EP2195423A1 - Glucoamylase variants with altered properties - Google Patents

Glucoamylase variants with altered properties

Info

Publication number
EP2195423A1
EP2195423A1 EP08742678A EP08742678A EP2195423A1 EP 2195423 A1 EP2195423 A1 EP 2195423A1 EP 08742678 A EP08742678 A EP 08742678A EP 08742678 A EP08742678 A EP 08742678A EP 2195423 A1 EP2195423 A1 EP 2195423A1
Authority
EP
European Patent Office
Prior art keywords
glucoamylase
seq
variant
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08742678A
Other languages
German (de)
English (en)
French (fr)
Inventor
Wolfgang Aehle
Richard R. Bott
Igor Nikolaev
Martijn Scheffers
Piet Van Solingen
Casper Vroemen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39720559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2195423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2007/021683 external-priority patent/WO2008045489A2/en
Application filed by Danisco US Inc filed Critical Danisco US Inc
Priority to ES12164788.7T priority Critical patent/ES2518916T3/es
Priority to EP12164776.2A priority patent/EP2479264B1/en
Priority to DK12164776.2T priority patent/DK2479264T3/da
Priority to EP12164788.7A priority patent/EP2479265B1/en
Priority to PL12164788T priority patent/PL2479265T3/pl
Priority to DK12164788.7T priority patent/DK2479265T3/da
Priority to PL12164776T priority patent/PL2479264T3/pl
Publication of EP2195423A1 publication Critical patent/EP2195423A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • the present invention relates to variants of a parent glucoamylase having altered properties (e.g., improved thermostability and/or specific activity).
  • the present invention provides compositions comprising the variant glucoamylases, including starch hydrolyzing compositions, animal feed compositions and cleaning compositions.
  • the invention also relates to DNA constructs encoding the variants and methods of producing the glucoamylase variants in host cells.
  • Glucoamylase enzymes are starch hydrolyzing exo- acting carbohydrases, which catalyze the removal of successive glucose units from the non-reducing ends of starch or related oligo and polysaccharide molecules.
  • Glucoamylases can hydrolyze both the linear and branched glucosidic linkages of starch (e.g., amylose and amylopectin).
  • Glucoamylases are produced by numerous strains of bacteria, fungi, yeast and plants. Particularly interesting, and commercially important, glucoamylases are fungal enzymes that are extracellularly produced, for example from strains of Aspergillus (Svensson et al. (1983) Carlsberg Res. Commun. 48:529 - 544; Boel et al., (1984) EMBO J. 3: 1097 - 1 102; Hayashida et al., (1989) Agric. Biol. Chem.
  • glucoamylases are very important enzymes and have been used in a wide variety of applications that require the hydrolysis of starch ⁇ e.g. for producing glucose and other monosaccharides from starch).
  • Glucoamylases are used to produce high fructose corn sweeteners, which comprise over 50% of the sweetener market in the United States.
  • glucoamylases may be, and commonly are, used with alpha amylases in starch hydrolyzing processes to hydrolyze starch to dextrins and then glucose. The glucose may then be converted to fructose by other enzymes (e.g.
  • glucose isomerases glucose isomerases
  • crystallized or used in fermentations to produce numerous end products (e.g., ethanol, citric acid, lactic acid, succinate, ascorbic acid intermediates, glutamic acid, glycerol and 1 , 3-propanediol).
  • Ethanol produced by using glucoamylases in the fermentation of starch and/or cellulose containing material may be used as a source of fuel or for alcoholic consumption.
  • glucoamylases have been used successfully in commercial applications for many years, a need still exists for new glucoamylases having altered properties.
  • the present invention relates to isolated glucoamylase variants having one or more amino acid substitutions at a position corresponding to residue position: 10, 14, 15, 23, 42, 45, 46, 59, 60, 61 , 67, 68, 72, 73, 97, 98, 99, 102, 108, 1 10, 1 13, 1 14, 122, 124, 125, 133, 140, 144, 145, 147, 152, 153, 164, 175, 182, 204, 205, 214, 216, 219, 228, 229, 230, 231 , 236, 239, 240, 241 , 242, 244, 263, 264, 265, 268, 269, 276, 284, 291 , 300, 301 , 303, 310, 31 1 , 313, 316, 338, 342, 344, 346, 349, 359, 361 , 364, 379, 382, 390, 391 , 393, 394, 408, 410, 4
  • the parent glucoamylase comprises the sequence of SEQ ID NOs: 1 , 4, 5, 6, 7, 8, or 9.
  • a parent glucoamylase comprises SEQ ID NO: 2.
  • the parent glucoamylase is obtained from a Trichoderma spp., an Aspergillus spp., a Humicola spp., a Penicillium spp., a Talaromyces spp, or a Schizosaccharmyces spp.
  • the equivalent position in a parent is determined by sequence identity.
  • the parent glucoamylase has at least 80% sequence identity to SEQ ID NO: 2.
  • the equivalent position in a parent is determined by structural identity to SEQ ID NOs: 2 or 3.
  • the variant has a substitution in a position chosen from: T10D/F/G/K/L/M/P/R/S; L14E/H; N15D/N; P23A/G; F59A/G; K60F/H; N61D/I/L/QAg/V/W; R65A/C/G/I/K/M/S/V/Y; T67C/I/K/M/T;
  • T241C/E/H/L/M/P/S/T/V N242C/F/H/M/T/V/W; N263H/K/P; L264A/C/E/F/L/S; G265E/G/H/I/K/R/T; A268C/D/E/F/G/I/K/L/P/R/T/W; G269E; D276S; V284R/T/V/Y/A/E/F/H/K/N/P/W; P300K/R; A301 E/K/L/P/S/W; A303C/D/F/H/I/K/L/N/R/T/V/W/Y; A31 1N/P/Q/S/Y; V338P/Q/S/Y; T342N/V; S344A/T; T346G/H/M/N/P/Q/Y; A349L/I/K/M
  • the present invention relates to an isolated glucoamylase variant comprising one or more amino acid substitutions at a position corresponding to positions 10, 14, 15, 23, 42, 45, 46, 59,60,61,67,68,72,73,97,98,99, 102, 108, 110, 113, 114, 122, 124, 125, 133,140, 144, 145, 147, 152, 153, 164, 175, 182, 204, 205, 214, 216, 219, 228, 229, 230, 231, 236, 239, 240, 241, 242, 244, 263, 264, 265, 268, 269, 276, 284, 291, 300, 301, 303, 310, 311, 313, 316, 338, 342, 344, 346, 349, 359, 361, 364, 379, 382, 390, 391, 393, 394, 408, 410, 415, 417, 418, 430, 431, 433, 436,
  • the glucoamylase variants comprise one or more amino acid substitutions corresponding to a position chosen from positions 10, 14, 15,23,59,60,61,65,67,68,72,73,97,98,99, 102, 110, 113, 133, 140, 144, 145, 147, 152, 153, 164, 182, 204, 205, 214, 216, 219, 228, 229, 230, 231, 236, 239, 241, 242, 263, 264, 265, 268, 269, 276, 284, 291, 300, 301, 303, 311, 338, 342, 344, 346, 349, 359, 361, 364, 379, 382, 390, 391, 393, 394, 410, 417, 418, 430, 431, 433, 442, 444, 448, and 451 of SEQ ID NO: 2 or 3.
  • the glucoamylase variants comprise one or more amino acid substitutions at a position corresponding to positions 61, 67, 72, 97, 102, 133, 205, 219, 228, 230, 231, 239, 263, 268, 291, 342, 394, 430, 431 and 451 of SEQ ID NO: 2 or SEQ ID NO: 3.
  • the glucoamylase variants have one or more amino acid substitutions corresponding to at least one of the following: T67M, A72Y, S97N, S102M, I133T, T205Q, Q219S, W228M, S230F, S230G, S230N, S230R, S231L, I239V, I239Y, N263P, A268C, A268G, A268K, S291A, T342V, K394S, T430K, A431Q, S451K of SEQ ID NO:2orSEQIDNO:3.
  • the glucoamylase variants of the invention have an altered property compared to a parent glucoamylase.
  • the altered property is an increase in specific activity compared to a glucoamylase comprising the sequence of SEQ ID NO: 2, SEQ ID NO: 3 or a parent glucoamylase having at least 80% sequence identity to SEQ ID NO: 2.
  • the glucoamylase variant has increased specific activity compared to the glucoamylase comprising SEQ ID NO: 2.
  • the glucoamylase variants comprise one or more amino acid substitutions corresponding to a position chosen from positions: 10, 14, 15, 23, 59, 60, 61, 65, 67, 68, 72, 73,97,98,99, 102, 110, 113, 133, 140, 144, 145, 147, 152, 153, 164, 182,204,205,214,216,219,228, 229, 230, 231, 236, 239, 241, 242, 263, 264, 265, 268, 269, 276, 284, 291, 300, 301, 303, 311, 338, 342, 344, 346, 349, 359, 361, 364, 379, 382, 390, 391, 393, 394, 410, 417, 418, 430, 431, 433, 442, 444, 448, and 451 of SEQ IDNO: 2 or 3.
  • the glucoamylase variants of the invention have increased thermo stability compared to a glucoamylase comprising the sequence of SEQ ID NO: 2, SEQ ID NO: 3 or a parent glucoamylase having at least 80% sequence identity to SEQ ID NO: 2.
  • the glucoamylase variant has increased thermo stability compared to the glucoamylase comprising SEQ ID NO: 2 or SEQ ID NO: 3.
  • the glucoamylase variants of the invention comprise one or more amino acid substitutions corresponding to a position chosen from positions: 10, 15, 23, 42, 59, 60, 61, 68, 72, 73, 97, 98, 99, 102, 1 14, 133, 140, 144, 147, 152, 153, 164, 182, 204, 205, 214, 216, 228, 229, 230, 231 , 236, 241, 242, 263, 264, 265, 268, 269, 276, 284, 291 , 300, 301 , 303, 31 1 , 338, 342, 344, 346, 349, 359, 361 , 364, 379, 382, 390, 391, 393, 394, 410, 417, 430, 431 , 433, 436, 442, 443, 444, 448, and 451 of SEQ ID NO: 2 or SEQ ID NO: 3.
  • the glucoamylase variants of the invention comprise one or more amino acid substitutions corresponding to a position chosen from positions: 10, 42, 68, 73, 97, 1 14, 153, 229, 231 , 236, 264, 291 , 301 , 344, 361 , 364, 417, and 433 of SEQ ID NO: 2 or SEQ ID NO: 3.
  • the glucoamylase variants comprise one or more amino acid substitutions corresponding to a position chosen from positions 68, 73, 1 14, 153, 236, 344, 361 , 364 and 433 of SEQ ID NO: 2 or SEQ ID NO: 3.
  • the glucoamylase variants comprise one or more amino acid substitutions corresponding to at least one of the following: TlOS, T42V, E68C, E68M, G73F, G73W, Kl 14M, Kl 14T, N153A, N153S, N153V, W228V, D236R, G361 D, G361 E, G361 P, G361 Y, A364D, A364E, A364F, A364G, A364K, A365L, A365R, R433C, R433G, R433L, R433N, R433S, R433V, and I436H of SEQ ID NO: 2 or SEQ ID NO: 3.
  • the glucoamylase variants of the invention have increased specific activity and increased thermostability compared to a glucoamylase comprising the sequence of SEQ ID NO: 2, SEQ ID NO: 3 or a parent glucoamylase having at least 80% sequence identity to SEQ ID NO: 2.
  • the glucoamylase variants of the invention comprise one or more amino acid substitutions corresponding to a position chosen from positions: 10, 15, 59, 61, 68, 72, 73, 97, 99, 102, 133, 140, 153, 182, 204, 205, 214, 228, 229, 230, 231 , 236, 241, 242, 264, 265, 268, 275, 284, 291 , 300, 301 , 303, 31 1 , 338, 344, 346, 359, 361 , 364, 370, 382, 391 , 393, 394, 410, 417, 430, 431 , 433, 444, 448, and 451 of SEQ ID NO: 2 or SEQ ID NO: 3.
  • the glucoamylase variants comprise one or more amino acid substitutions corresponding to a position chosen from position 228, 230, 231 , 268, 291 , 417, 433, and 451 of SEQ ID NO: 2 or SEQ ID NO:3.
  • the glucoamylase variants have one or more amino acid substitutions corresponding to at least one of the following: W228A, W228F, W228H, W228M, S230F, S230G, S230R, S231 L, A268C, A268G, S291 A, L417R, R433Y, and S451 K of SEQ ID NO: 2 or SEQ ID NO:3.
  • the invention relates to an isolated polynucleotide encoding any one of the glucoamylase variants encompassed by the invention.
  • the invention relates to a host cell comprising a polynucleotide encoding a glucoamylase encompassed by the invention.
  • the invention is related to enzyme compositions comprising one or more glucoamylase variants encompassed by the invention.
  • the enzyme compositions will include additional enzymes such as one or more alpha amylases.
  • the enzyme compositions will be used in a starch conversion process, an alcohol fermentation process and/or an animal feed formulation.
  • the invention relates to a method of producing a variant glucoamylase encompassed by the invention comprising transforming a host cell with a polynucleotide encoding a glucoamylase variant of the invention; cult ⁇ ring the host cell under conditions suitable for the expression and production of said glucoamylase variant and producing said variant.
  • the glucoamylase variant is recovered from the culture.
  • FIG. I A illustrates a Trichoderma reesei glucoamylase (TrGA) having 632 amino acids (SEQ ID NO: 1).
  • the signal peptide is underlined, the catalytic region (SEQ ID NO:3) starting with amino acid residues SVDDFI (SEQ ID NO: 12) and having 453 amino acid residues is in bold; the linker region is in italics and the starch binding domain (SBD) is both italics and underlined.
  • the mature protein which includes the catalytic domain (SEQ ID NO:3), linker region (SEQ ID NO: 10) and starch binding domain (SEQ ID NO: 1 1) is represented by SEQ ID NO:2.
  • IB illustrates the cDNA (SEQ ID NO:4) which codes for the TrGA.
  • Fig. 1C illustrates the precursor and mature protein TrGA domains.
  • FIG. 2 illustrates the destination plasmid pDONR-TrGA which includes the cDNA (SEQ ID NO:4) of the TrGA.
  • FIG. 3 illustrates the plasmid pTTT-Dest.
  • FIG. 4 illustrates the final expression vector pTTT-TrGA.
  • FIGS. 5A - 5B illustrate an alignment comparison of the catalytic domains of parent glucoamylases including glucoamylase derived from Aspergillus awamori (AaGA) (SEQ ID NO:5); Aspergillus niger (AnGA) (SEQ ID NO:6); Aspergillus oryzae (AoGA) (SEQ ID NO:7); Trichoderma reesei (TrGA) (SEQ ID NO:3); Humicola grisea (HgGA) (SEQ ID NO:8); and Hypocrea vinosa (HvGA) (SEQ ID NO:9). Identical amino acids are indicated by an asterisk
  • FIG. 5C illustrates the Talaromyces glucoamylase (TeGA) mature protein sequence
  • FIG. 6 is a comparison of the three dimensional structures of Trichoderma glucoamylase
  • black SEQ ID NO:2
  • Aspergillus awamori glucoamylase grey
  • the side is measured in reference to the active site and the active site entrance is at the "top" of the molecule.
  • FIG. 7 is a comparison of the three dimensional structures of Trichoderma glucoamylase (black) and Aspergillus awamori glucoamylase (grey) viewed from the top. The active site entrance is at the "top” of the molecule. DETAILED DESCRIPTION OF THE INVENTION I. Definitions
  • glucoamylase (EC 3.2.1.3) refers to an enzyme that catalyzes the release of D-glucose from the non-reducing ends of starch and related oligo-and polysaccharides.
  • parent or “parent sequence” refers to a sequence that has sequence and/or structural identity with TrGA (e.g., SEQ ID NOs: 1 , 2 and/or 3) and is a native or naturally occurring sequence in a host cell.
  • TrGA refers to a Trichoderma reesei glucoamylase sequence having the mature protein sequence illustrated in SEQ ID NO:2, which includes the catalytic domain having the sequence illustrated in SEQ ID NO:3.
  • the isolation, cloning and expression of the TrGA are described in WO 2006/060062 and U.S. Pat. Pub. No. 2006/0094080 published May 4, 2006 which are incorporated herein by reference.
  • the TrGA is also considered a parent glucoamylase sequence.
  • the parent sequence refers to a TrGA that is the starting point for protein engineering.
  • the numbering of the glucoamylase amino acids herein is based on the sequence of the TrGA glucoamylase sequence (SEQ ID NO: 2 and SEQ ID NO: 3).
  • TrGA mature form of a protein or polypeptide
  • a mature form of the TrGA includes the catalytic domain, linker region and starch binding domain having the amino acid sequence of SEQ ID NO:2.
  • Trichoderma glucoamylase homologues refers to parent glucoamylases having at least 80% amino acid sequence identity to the TrGA sequence (SEQ ID NO: 1 , SEQ ID NO:2 or SEQ ID NO:3) and which glucoamylases retain the functional characteristics of a glucoamylase.
  • a "homologous sequence” means a nucleic acid or polypeptide sequence having at least 100%, at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 88%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, or at least 45% sequence identity to a nucleic acid sequence or polypeptide sequence when optimally aligned for comparison, wherein the function of the candidate nucleic acid sequence or polypeptide sequence is essentially the same as the nucleic acid sequence or polypeptide sequence said candidate homologous sequence is being compared with.
  • homologous sequences have between 85% and 100% sequence identity, while in other embodiments there is between 90% and 100% sequence identity, and in other embodiments, there is 95% and 100% sequence identity.
  • the candidate homologous sequence or parent is compared with the TrGA nucleic acid sequence or mature protein sequence. The sequence identity can be measured over the entire length of the parent or homologous sequence.
  • glucoamylase variant As used herein, the terms "glucoamylase variant", “variant” and “TrGA variant” are used in reference to glucoamylases that are similar to a parent glucoamylase sequence (e.g., the TrGA or Trichoderma glucoamylase homologues) but have at least one substitution, deletion or insertion in their amino acid sequence that makes them different in sequence from a parent glucoamylase. In some cases they have been manipulated/engineered to include at least one substitution, deletion or insertion in their amino acid sequence that makes them different in sequence from a parent glucoamylase.
  • TrGA Trichoderma glucoamylase homologues
  • catalytic domain refers to a structural region of a polypeptide, which contains the active site for substrate hydrolysis.
  • linker refers to a short amino acid sequence generally having between 3 and 40 amino acid residues that covalently bind an amino acid sequence comprising a starch binding domain with an amino acid sequence comprising a catalytic domain.
  • starch binding domain refers to an amino acid sequence that binds preferentially to a starch substrate.
  • the expression product of the mutant sequence is a variant protein with an altered amino acid sequence relative to the parent.
  • the expression product may have an altered functional capacity (e.g., enhanced enzymatic activity).
  • polypeptide refers to any characteristic or attribute of a polypeptide that can be selected or detected. These properties include, but are not limited to oxidative stability, substrate specificity, catalytic activity, thermal stability, pH activity profile, resistance to proteolytic degradation, K M , K CAT> K CAT /K M ratio, protein folding, ability to bind a substrate and ability to be secreted.
  • nucleic acid refers to any characteristic or attribute of a nucleic acid that can be selected or detected. These properties include, but are not limited to, a property affecting gene transcription (e.g., promoter strength or promoter recognition), a property affecting RNA processing (e.g., RNA splicing and RNA stability), a property affecting translation (e.g., regulation, binding of mRNA to ribosomal proteins).
  • a property affecting gene transcription e.g., promoter strength or promoter recognition
  • RNA processing e.g., RNA splicing and RNA stability
  • translation e.g., regulation, binding of mRNA to ribosomal proteins.
  • thermostability refers to a higher retained starch hydrolytic activity over time as compared to another reference (e.g., parent) glucoamylase.
  • thermostability in the context of a property such as thermostability refers to a lower retained starch hydrolytic activity over time as compared to another reference glucoamylase.
  • specific activity The specific activity is defined as the activity per mg of glucoamylase protein. In some embodiments, the activity for glucoamylase is determined by the ethanol assay described herein and expressed as the amount of glucose which is produced from the starch substrate. In some embodiments, the protein concentration can be determined using the Caliper assay described herein.
  • the terms “active” and “biologically active” refer to a biological activity associated with a particular protein. It follows that the biological activity of a given protein refers to any biological activity typically attributed to that protein by those skilled in the art. For example, an enzymatic activity associated with a glucoamylase is hydrolytic and, thus an active glucoamylase has hydrolytic activity.
  • polynucleotide and nucleic acid used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides.
  • DNA construct transforming DNA
  • expression vector a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases.
  • the DNA construct, transforming DNA or recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment.
  • the recombinant expression cassette portion of an expression vector, DNA construct or transforming DNA includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter.
  • expression vectors have the ability to incorporate and express heterologous DNA fragments in a host cell.
  • vector refers to a polynucleotide construct designed to introduce nucleic acids into one or more cell types. Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, cassettes and the like.
  • the term "introduced” refers to any method suitable for transferring the nucleic acid sequence into the cell. Such methods for introduction include but are not limited to protoplast fusion, transfection, transformation, conjugation, and transduction.
  • the terms “transformed” and “stably transformed” refer to a cell that has a non- native (heterologous) polynucleotide sequence integrated into its genome or as an episomal plasmid that is maintained for at least two generations.
  • selectable marker refers to a nucleic acid (e.g., a gene) capable of expression in host cells which allows for ease of selection of those hosts containing the vector.
  • selectable markers are genes that confer antimicrobial resistance or a metabolic advantage on the host cell to allow cells containing the exogenous DNA to be distinguished from cells that have not received any exogenous sequence during the transformation.
  • promoter refers to a nucleic acid sequence that functions to direct transcription of a downstream gene.
  • the promoter together with other transcriptional and translational regulatory nucleic acid sequences (also termed “control sequences") is necessary to express a given gene.
  • control sequences also termed “control sequences”
  • transcriptional and translational regulatory sequences include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences.
  • a nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA encoding a secretory leader i.e., a signal peptide
  • DNA for a polypeptide is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide.
  • "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase.
  • the term "gene” refers to a polynucleotide (e.g., a DNA segment), that encodes a polypeptide and includes regions preceding and following the coding regions as well as intervening sequences (introns) between individual coding segments (exons).
  • homologous genes refers to a pair of genes from different, but usually related species, which correspond to each other and which are identical or very similar to each other.
  • the term encompasses genes that are separated by speciation (i.e., the development of new species) (e.g., orthologous genes), as well as genes that have been separated by genetic duplication (e.g., paralogous genes).
  • ortholog and “orthologous genes” refer to genes in different species that have evolved from a common ancestral gene (i.e., a homologous gene) by speciation. Typically, orthologs retain the same function during the course of evolution. Identification of orthologs finds use in the reliable prediction of gene function in newly sequenced genomes.
  • paralog and “paralogous genes” refer to genes that are related by duplication within a genome. While orthologs retain the same function through the course of evolution, paralogs evolve new functions, even though some functions are often related to the original one.
  • paralogous genes include, but are not limited to genes encoding trypsin, chymotrypsin, elastase, and thrombin, which are all serine proteinases and occur together within the same species.
  • homology refers to sequence similarity or identity, with identity being preferred. This homology is determined using standard techniques known in the art (See e.g., Smith and Waterman, ( ⁇ 9S ⁇ ) Adv. Appl. Math., 2:482; Needleman and Wunsch, (1988) J. MoI. Biol., 48:443; Pearson and Lipman, (1988) Proc. Natl. Acad.
  • the "percent (%) nucleic acid sequence identity” or “percent (%) amino acid sequence identity” is defined as the percentage of nucleotide residues or amino acid residues in a candidate sequence that are identical with the nucleotide residues or amino acid residues of the starting sequence (i.e., TrGA). The sequence identity can be measured over the entire length of the starting sequence (i.e., TrGA SEQ ID NO:2 or 3).
  • Homologous sequences are determined by known methods of sequence alignment. A commonly used alignment method is BLAST described by Altschul et al., (Altschul et al., (1990) J. MoI. Biol.,
  • the HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched.
  • a % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region.
  • the "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).
  • Other methods find use in aligning sequences.
  • One example of a useful algorithm is PILEUP.
  • PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pair- wise alignments. It can also plot a tree showing the clustering relationships used to create the alignment.
  • PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (Feng and Doolittle, (1987) J. MoI. Evol., 35:351 -360). The method is similar to that described by Higgins and Sharp (Higgins and Sharp, (1989) CABIOS 5: 151 -153).
  • Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.
  • the term “optimal alignment” refers to the alignment giving the highest percent identity score.
  • An "equivalent position” refers to an optimal alignment between two sequences. For example using Figs.
  • position 491 in TrGA (SEQ ID NO: 2) is C491 ; the equivalent position fox Aspergillus niger is position C509; and the equivalent position for Aspergillus crwamori is position Q538. See Figure 8 for an exemplary alignment of the three-dimensional sequence.
  • hybridization refers to the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as known in the art.
  • a nucleic acid sequence is considered to be "selectively hybridizable" to a reference nucleic acid sequence if the two sequences specifically hybridize to one another under moderate to high stringency hybridization and wash conditions.
  • Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe.
  • Tm melting temperature
  • maximum stringency typically occurs at about Tm-5°C (5° below the Tm of the probe); “high stringency” at about 5-10°C below the Tm; “intermediate stringency” at about 10-20°C below the Tm of the probe; and “low stringency” at about 20- 25°C below the Tm.
  • maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe; while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs.
  • Moderate and high stringency hybridization conditions are well known in the art.
  • An example of high stringency conditions includes hybridization at about 42°C in 50% formamide, 5X SSC, 5X Denhardt's solution, 0.5% SDS and 100 ⁇ g/ml denatured carrier DNA followed by washing two times in 2X SSC and 0.5% SDS at room temperature and two additional times in 0.1 X SSC and 0.5% SDS at 42°C.
  • moderate stringent conditions include an overnight incubation at 37°C in a solution comprising 20% formamide, 5 x SSC (15OmM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in Ix SSC at about 37 - 50°C.
  • Those of skill in the art know how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
  • recombinant includes reference to a cell or vector, that has been modified by the introduction of a heterologous or homologous nucleic acid sequence or that the cell is derived from a cell so modified.
  • recombinant cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all as a result of deliberate human intervention.
  • mutated DNA sequences are generated with site saturation mutagenesis in at least one codon. In other embodiments, site saturation mutagenesis is performed for two or more codons.
  • mutant DNA sequences have more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, more than 95%, more than 98% or more than 99% homology with the parent sequence.
  • mutant DNA is generated in vivo using any known mutagenic procedure such as, for example, radiation, nitrosoguanidine and the like. The desired DNA sequence is then isolated and used in the methods provided herein.
  • heterologous protein refers to a protein or polypeptide that does not naturally occur in the host cell.
  • homologous protein refers to a protein or polypeptide native or naturally occurring in a cell and includes native proteins that are over-expressed in the cell whether by recombinant DNA technology or naturally.
  • An enzyme is "over-expressed” in a host cell if the enzyme is expressed in the cell at a higher level than the level at which it is expressed in a corresponding wild-type cell.
  • JCBN Biochemical Nomenclature
  • Variants of the invention are described by the following nomenclature: [original amino acid residue/position/substituted amino acid residue].
  • the substitution of leucine for arginine at position 76 is represented as R76L.
  • the substitution is represented as 1 ) Q172C, Q172D or Q172R; 2) Q172C, D, or R or c) Q172C/D/R.
  • a position suitable for substitution is identified herein without a specific amino acid suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in the position.
  • a variant glucoamylase contains a deletion in comparison with other glucoamylases the deletion is indicated with "*".
  • a deletion at position R76 is represented as R76*.
  • a deletion of two or more consecutive amino acids is indicated for example as (76 - 78)*.
  • a "prosequence” is an amino acid sequence between the signal sequence and mature protein that is necessary for the secretion of the protein. Cleavage of the pro sequence will result in a mature active protein.
  • the term “signal sequence” or “signal peptide” refers to any sequence of nucleotides and/or amino acids which may participate in the secretion of the mature or precursor forms of the protein. This definition of signal sequence is a functional one, meant to include all those amino acid sequences encoded by the N-terminal portion of the protein gene, which participate in the effectuation of the secretion of protein. They are often, but not universally, bound to the N-terminal portion of a protein or to the N-terminal portion of a precursor protein.
  • the signal sequence may be endogenous or exogenous.
  • the signal sequence may be that normally associated with the protein (e.g., glucoamylase), or may be from a gene encoding another secreted protein.
  • precursor form of a protein or peptide refers to a mature form of the protein having a prosequence operably linked to the amino or carbonyl terminus of the protein.
  • the precursor may also have a "signal" sequence operably linked, to the amino terminus of the prosequence.
  • the precursor may also have additional polypeptides that are involved in post-translational activity (e.g., polypeptides cleaved therefrom to leave the mature form of a protein or peptide).
  • “Host strain” or “host cell” refers to a suitable host for an expression vector comprising DNA according to the present invention.
  • the terms "derived from” and “obtained from” refer to not only a glucoamylase produced or producible by a strain of the organism in question, but also a glucoamylase encoded by a DNA sequence isolated from such strain and produced in a host organism containing such DNA sequence. Additionally, the term refers to a glucoamylase which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the glucoamylase in question.
  • a "derivative" within the scope of this definition generally retains the characteristic hydrolyzing activity observed in the wild-type, native or parent form to the extent that the derivative is useful for similar purposes as the wild-type, native or parent form.
  • Functional derivatives of glucoamylases encompass naturally occurring, synthetically or recombinantly produced peptides or peptide fragments which have the general characteristics of the glucoamylases of the present invention.
  • isolated or “purified” refers to a material that is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • an isolated protein is more than 10% pure, preferably more than 20% pure, and even more preferably more than 30% pure, as determined by SDS-PAGE.
  • Further aspects of the invention encompass the protein in a highly purified form (i.e., more than 40% pure, more than 60% pure, more than 80% pure, more than 90% pure, more than 95% pure, more than 97% pure, and even more than 99% pure), as determined by SDS-PAGE.
  • a highly purified form i.e., more than 40% pure, more than 60% pure, more than 80% pure, more than 90% pure, more than 95% pure, more than 97% pure, and even more than 99% pure.
  • the methods provide means to introduce random mutations which were not members of the predefined set of mutations.
  • the methods include those set forth in USP 6,582,914, hereby incorporated by reference.
  • combinatorial mutagenesis methods encompass commercially available kits (e.g., QU ⁇ CCHANGE® Multisite, Stratagene, San Diego, CA).
  • the term "library of mutants” refers to a population of cells which are identical in most of their genome but include different homologues of one or more genes. Such libraries can be used, for example, to identify genes or operons with improved traits.
  • dry solids content DS or ds
  • dry solids content refers to the total solids of a slurry in % on a dry weight basis.
  • initial hit refers to a variant that was identified by screening a combinatorial consensus mutagenesis library. In embodiments, initial hits have improved performance characteristics, as compared to the starting gene. [80] As used herein, the term “improved hit” refers to a variant that was identified by screening an enhanced combinatorial consensus mutagenesis library.
  • target property refers to the property of the starting gene that is to be altered. It is not intended that the present invention be limited to any particular target property. However, in some embodiments, the target property is the stability of a gene product (e.g., resistance to denaturation, proteolysis or other degradative factors), while in other embodiments, the level of production in a production host is altered. Indeed, it is contemplated that any property of a starting gene will find use in the present invention. Other definitions of terms may appear throughout the specification. [83] Before the exemplary embodiments are described in more detail, it is to be understood that this invention is not limited to particular embodiments described herein, as such may, vary.
  • An objective of the present invention was to alter properties, such as thermal stability and/or specific activity of parent glucoamylases and in particular Trichoderma reesei glucoamylase (TrGA), to obtain glucoamylase variants having the altered properties which would be useful in various applications such as starch conversion or alcohol fermentation processes.
  • properties such as thermal stability and/or specific activity of parent glucoamylases and in particular Trichoderma reesei glucoamylase (TrGA)
  • the present invention provides a glucoamylase variant of a parent glucoamylase.
  • the parent glucoamylase can comprise a sequence that has sequence and/or structural identity with TrGA (SEQ ID NOs:2 and/or 3).
  • the parent glucoamylase comprises an amino acid sequence as illustrated in SEQ ID NOs: 1 , 2, 3, 5, 6, 7, 8 or 9.
  • the parent glucoamylase is a homologue.
  • the parent glucoamylase has at least 50% sequence identity, at least 60% sequence identity, at least 70% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 88% sequence identity, at least 90% sequence identity, at least 93% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity and also at least 99% sequence identity with the TrGA amino acid sequence of SEQ ID NO: 2.
  • the parent glucoamylase comprises a catalytic domain having an amino acid sequence having at least 50% amino acid sequence identity, at least 60% amino acid sequence identity, at least 70% amino acid sequence identity, at least 80% amino acid sequence, at least 85% amino acid sequence identity, at least 90% amino acid sequence identity, at least 93% amino acid sequence identity, at least 95% amino acid identity, at least 97% amino acid sequence identity and at least 99% amino acid sequence identity with one or more of the amino acid sequences illustrated in SEQ ID NO: 1 , 2, 3, 5, 6, 7, or 8.
  • the parent glucoamylase will have at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity, at least 97% sequence identity and also at least 98% sequence identity with the catalytic domain of the TrGA amino acid sequence of SEQ ID NO:3.
  • the parent glucoamylase can be encoded by a DNA sequence which hybridizes under medium, high or stringent conditions with a DNA encoding a glucoamylase having one of the amino acid sequences of SEQ ID NO: 1 , 2 or 3.
  • the parent glucoamylase with at least 50% sequence identity, at least 60% amino acid sequence identity, at least 70% amino acid sequence identity, at least 80% amino acid sequence identity, at least 90% amino acid sequence identity, at least 95% amino acid identity and at least 97% amino acid sequence identity also has structural identity with SEQ ID NOs:2 and/or 3.
  • the parent glucoamylase is a native or naturally occurring sequence in a host cell, in some embodiments, the parent glucoamylase is a naturally occurring variant. In some embodiments, the parent glucoamylase is a variant that has been engineered and/or a hybrid glucoamylase. [92] Predicted structures and known sequences of glucoamylases are conserved among fungal species (Coutinho et al., (1994) Protein Eng., 7:393 - 400 and Coutinho et al., (1994), Protein Eng., 7: 749-760). In some embodiments, the parent glucoamylase is a filamentous fungal glucoamylase.
  • the parent glucoamylase is obtained from a Trichoderma strain (e.g., T. reesei, T. longibrachiatum, T. strictipilis, T. asperellum, T. konilangbra and T. hazianum), an Aspergillus strain (e.g. A. niger, A. nidulans, A. kawachi, A. awamori and A. orzyae), a Talaromyces strain (e.g. T. emersonii, T. thermophilus, and T. duponti), a Hypocrea strain (e.g. H. gelatinosa , H. orientalis, H.
  • a Trichoderma strain e.g., T. reesei, T. longibrachiatum, T. strictipilis, T. asperellum, T. konilangbra and T. hazianum
  • an Aspergillus strain e.g
  • a Fusarium strain e.g., F. oxysporum, F. roseum, and F. venenatum
  • a Neurospora strain e.g., N. crassa
  • a Humicola strain e.g., H. grisea, H. insolens and H. lanuginosa
  • Penicillium strain e.g. P. notation or P. chrysogemim
  • Saccharomycopsis strain e.g. S. f ⁇ uligera
  • the parent glucoamylase is a bacterial glucoamylase.
  • the polypeptide may be obtained from a gram positive bacterial strain such as Bacillus (e.g., B. alkalophilus, B. amyloliquefaciens, B. lentus, B. licheniformis, B. stearothermophilus, B. subtilis and B. thuringiensis) or a Streptomyces strain ⁇ e.g., S. lividans).
  • the parent glucoamylase will comprise an amino acid sequence having at least 90% sequence identity, at least 93% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity and also at least 99% sequence identity with the catalytic domain of the Aspergillus parent glucoamylase of SEQ ID NO:5 or SEQ ID NO:6.
  • the parent glucoamylase will comprise an amino acid sequence having at least 90% sequence identity, at least 95% sequence identity, at least 97% sequence identity and also at least 99% sequence identity with the catalytic domain of the Humicola grisea (HgGA) parent glucoamylase of SEQ ID NO: 8.
  • the parent glucoamylase has at least 50% sequence identity, at least 60% sequence identity, at least 70% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 88% sequence identity, at least 90% sequence identity, at least 93% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity and also at least 99% sequence identity with the TrGA amino acid sequence of SEQ ID NO: 2 or 3 and has structural identity to the glucoamylase of SEQ ID NO:2 or 3.
  • a Trichoderma glucoamylase homologue will be obtained from a Trichoderma or Hypocrea strain. Some Trichoderma glucoamylase homologues are described in US Pat. Pub. No. 2006/0094080 and reference is made specifically to amino acid sequences set forth in SEQ ID NOs: 17 - 22 and 43 - 47 of said reference.
  • the parent glucoamylase is TrGA comprising the amino acid sequence of SEQ ID NO:2 or a Trichoderma glucoamylase homologue having at least 80%, at least 85%, at least 88%, at least 90%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to the TrGA sequence.
  • a parent glucoamylase can be isolated and/or identified using standard recombinant DNA techniques. Any standard techniques can be used that are known to the skilled artisan. For example, probes and/or primers specific for conserved areas of the glucoamylase can be used to identify homologues in bacterial or fungal cells (the catalytic domain, the active site, etc.). Alternatively degenerate PCR can be used to identify homologues in bacterial or fungal cells. In some cases, known sequences, such as in a database, can be analyzed for sequence and/or structural homology to one of the known glucoamylases, including SEQ ID NOs: 1 , 2 or 3.
  • Glucoamylase Structural Homology can also be used to identify glucoamylase activity in a bacterial or fungal cell. Proteins having glucoamylase activity can be isolated and reverse sequenced to isolate the corresponding DNA sequence. Such methods are known to the skilled artisan. Glucoamylase Structural Homology:
  • the central dogma of molecular biology is that the sequence of DNA encoding a gene for a particular enzyme, determines the amino acid sequence of the protein, this sequence in turn determines the three-dimensional folding of the enzyme. This folding brings together disparate residues that create a catalytic center and substrate binding surface and this results in the high specificity and activity of the enzymes in question.
  • Glucoamylases consist of as many as three distinct structural domains, a catalytic domain of approximately 450 residues which is structurally conserved, generally followed by a linker region consisting of between 30 and 80 residues which are connected to a starch binding domain of approximately 100 residues.
  • the structure of the Trichoderma reesei glucoamylase with all three regions intact was determined to 1.8 Angstrom resolution herein (see Table 9 and Examples 8 and 9).
  • the catalytic structure was aligned with the coordinates of the catalytic domain from Aspergillus awamorii strain Xl OO that was determined previously (Aleshin, et al (1994) JMo/ Biol 238: 575-591).
  • the Aspergillus awamori crystal structure only included the catalytic domain. As seen in Figures 6 and 7 the structure of the catalytic domains overlap very closely and it is possible to identify equivalent residues based on this structural superposition. The inventors believe that all glucoamylases share the basic structure depicted in Figures 6 and 7. The conservation of structure in the glucoamylase molecule correlates with the conservation of activity and a conserved mechanism of action for all glucoamylases. Given this high homology, site specific variants of the Trichoderma glucoamylase resulting in altered function would also have similar structural and therefore functional consequences in other glucoamylases.
  • the present invention is not limited to the variants of the parent Trichoderma glucoamylase disclosed in Figure 1 , but extends to variants of parent glucoamylases comprising amino acid residues at positions which are "equivalent" to the particular identified residues in Trichoderma reesei glucoamylase (SEQ ID NO:2).
  • the parent glucoamylase is a Talaromyces GA and the substitutions are made at the equivalent amino acid residue positions in Talaromyces glucoamylase (see e.g. SEQ ID NO:308, Figure 5C) as those described herein.
  • the parent glucoamylase comprises SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:3; SEQ ID NO:8; and SEQ ID NO:9 (See Figures 5A- 5B).
  • the parent glucoamylase is a Penicillium glucoamylase, such as Penicillium chrysogenum.
  • Structural identity determines whether the amino acid residues are equivalent. Structural identity is a one-to-one topological equivalent when the two structures (three dimensional and amino acid structures) are aligned. A residue (amino acid) position of a glucoamylase is equivalent to a residue of T.
  • reesei glucoamylase if it is either homologous (i.e., corresponding in position in either primary or tertiary structure) or analogous to a specific residue or portion of that residue in T. reesei glucoamylase (having the same or similar functional capacity to combine, react, or interact chemically).
  • the amino acid sequence of a glucoamylase can be directly compared to Trichoderma reesei glucoamylase primary sequence and particularly to a set of residues known to be invariant in glucoamylases for which sequence is known.
  • Figures 5A and B herein shows the conserved residues between glucoamylases.
  • the residues equivalent to particular amino acids in the primary sequence of Trichoderma reesei glucoamylase are defined. Alignment of conserved residues can conserve 100% of such residues. However, alignment of greater than 75% or as little as 50% of conserved residues is also adequate to define equivalent residues, particularly when alignment based on structural identity is included.
  • glucoamylases from six organisms are aligned to provide the maximum amount of homology between amino acid sequences.
  • a comparison of these sequences shows that there are a number of conserved residues contained in each sequence as designated by an asterisk.
  • conserved residues thus, may be used to define the corresponding equivalent amino acid residues of Trichoderma reesei glucoamylase in other glucoamylases such as glucoamylase from Aspergillus niger.
  • Structural identity involves the identification of equivalent residues between the two structures.
  • Equivalent residues can be defined by determining homology at the level of tertiary structure (structural identity) for an enzyme whose tertiary structure has been determined by x-ray crystallography. Equivalent residues are defined as those for which the atomic coordinates of two or more of the main chain atoms of a particular amino acid residue of the Trichoderma reesei glucoamylase (N on N, CA on CA, C on C and O on O) are within 0.13nm and preferably 0.1 nm after alignment.
  • Alignment is achieved after the best model has been oriented and positioned to give the maximum overlap of atomic coordinates of non-hydrogen protein atoms of the glucoamylase in question to the Trichoderma reesei glucoamylase.
  • the best model is the crystal Iographic model giving the lowest R factor for experimental
  • Equivalent residues which are functionally analogous to a specific residue of Trichoderma reesei glucoamylase are defined as those amino acids of the enzyme which may adopt a conformation such that they either alter, modify or contribute to protein structure, substrate binding or catalysis in a manner defined and attributed to a specific residue of the Trichoderma reesei glucoamylase.
  • residues of the enzyme for which a tertiary structure has been obtained by x-ray crystallography
  • the atomic coordinates of at least two of the side chain atoms of the residue lie with 0.13nm of the corresponding side chain atoms of Trichoderma reesei glucoamylase.
  • the coordinates of the three dimensional structure of Trichoderma reesei glucoamylase are set forth in Table 9 and can be used as outlined above to determine equivalent residues on the level of tertiary structure.
  • the variants according to the invention include at least one substitution, deletion or insertion in the amino acid sequence of a parent glucoamylase that makes the variant different in sequence from the parent glucoamylase.
  • the variants of the invention will have at least 20%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97% and also at least 100% of the glucoamylase activity of TrGA (SEQ ID NO:2).
  • the variants according to the invention will comprise a substitution, deletion or insertion in at least one amino acid position of the parent TrGA (SEQ ID NO:2), or in an equivalent position in the sequence of another parent glucoamylase having at least 50%, at least 60%, at least 70%, at least 80%, at least 90% sequence identity to the TrGA sequence, including but not limited to; at least 93% sequence identity, at least 95%, at least 97%, and at least 99% sequence identity.
  • the parent glucoamylase will have structural identity to the TrGA sequence.
  • the variant according to the invention will comprise a substitution, deletion or insertion in at least one amino acid position of a fragment of the parent TrGA, wherein the fragment comprises the catalytic domain of the TrGA sequence (SEQ ID NO:3) or in an equivalent position in a fragment comprising the catalytic domain of a parent glucoamylase having at least 50%, at least 60%, at least 70%, at least 80% sequence identity to the fragment of the TrGA sequence, at least
  • the fragment will comprise at least 400, 425, 450, and/or 500 amino acid residues.
  • the fragment may include part of the linker region.
  • the variant will comprise a substitution, deletion or insertion in the amino acid sequence of a fragment of the TrGA sequence (SEQ ID NO: 2 or SEQ ID NO: 3). In some embodiments, the variant will have structural identity with the TrGA sequence (SEQ ID NOs: 2 or 3).
  • Structural identity with reference to an amino acid substitution means that the substitution occurs at the equivalent amino acid position in the homologous glucoamylase or parent glucoamylase.
  • the term equivalent position means a position that is common to two parent sequences which is based on an alignment of the amino acid sequence of the parent glucoamylase in question as well as alignment of the three-dimensional structure of the parent glucoamylase in question with the TrGA reference glucoamylase amino acid sequence and three-dimensional sequence. For example, with reference to Fig. 5, position 24 in TrGA (SEQ ID NO: 3) is D24 and the equivalent position for Aspergillus niger (SEQ ID NO.
  • the glucoamylase variant will have more than one substitution (e.g. two, three or four substitutions) as compared to a corresponding parent glucoamylase.
  • a glucoamylase variant comprises a substitution, deletion or insertion in at least one amino acid position in a position corresponding to the regions of non-conserved amino acids as illustrated in Figures 5A and 5B (e.g. amino acid positions corresponding to those positions which are not designated by"*" in Figures 5 A and 5B).
  • the variant comprises a substitution in at least one amino acid position in a position corresponding to the regions of non-conserved amino acids as illustrated in Figures 5A and 5B.
  • a glucoamylase variant comprises one or more substitutions in the following positions in the amino acid sequence set forth in SEQ ID NOs: 2 or 3: 10, 14, 15, 23, 42, 45, 46, 59, 60, 61 , 67, 68, 72, 73, 97, 98, 99, 102, 108, 1 10, 1 13, 1 14, 122, 124, 125, 133, 140, 144, 145, 147, 152, 153, 164, 175, 182, 204, 205, 214, 216, 219, 228, 229, 230, 231 , 236, 239, 240, 241 , 242, 244, 263, 264, 265, 268, 269, 276, 284, 291 , 300, 301 , 303, 310, 31 1 , 313, 316, 338, 342, 344, 346, 349, 3
  • the parent glucoamylase will have at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, and at least 99% sequence identity with SEQ ID NO: 2 or SEQ ID NO: 3.
  • the parent glucoamylase will be a Trichoderma glucoamylase homologue.
  • the variant will have altered properties.
  • the parent glucoamylase will have structural identity with the glucoamylase of SEQ ID NOs: 2 or 3.
  • the glucoamylase variant comprises one or more substitutions in the following positions in the amino acid sequence set forth in SEQ ID NO: 2 or 3: Tl O, L 14, N 15, P23, T42, P45, D46, F59, K60, N61 , T67, E68, A72, G73, S97, L98, A99, S102, K108, El 10, Ll 13, Kl 14, R122, Q124, R125, 1133, K140, N144, N145, Y147, S152, Nl 53, N164, F175, N182, A204, T205, S214, V216, Q219, W228, V229, S230, S231, D236, 1239, N240, T241 , N242, G244, N263, L264, G265, A268, G269, D276, V284, S291 , P300, A301 , A303, Y310, A31 1 , D313, Y316, V338, T
  • the variant of a glucoamylase parent comprises one or more substitutions in the following positions in the amino acid sequence set forth in SEQ ID NO:2 or 3: 10, 14, 15, 23, 59, 60, 61 , 65, 67, 68, 72, 73, 97, 98, 99, 102, 1 10, 1 13, 133, 140, 144, 145, 147, 152, 153, 164, 182, 204, 205, 214, 216, 219, 228, 229, 230, 231, 236, 239, 241, 242, 263, 264, 265, 268, 269, 276, 284, 291 , 300, 301 , 303, 31 1 , 338, 342, 344, 346, 349, 359, 361 , 364, 375, 379, 382, 390, 391 , 393, 394, 410, 417, 418, 430, 431 , 433, 442, 444, 448, and 451 or an equivalent
  • the parent glucoamylase will have 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, and at least 99% sequence identity with SEQ ID NO: 2 or SEQ ID NO: 3.
  • the parent glucoamylase will be a Trichoderma glucoamylase homologue.
  • the variant will have at least one altered property as compared to the parent glucoamylase. In some embodiments, the at least one altered property is specific activity.
  • the variant has one or more substitutions corresponding to one of the following positions: 61, 67, 72, 97, 102, 133, 205, 219, 228, 230, 231 , 239, 263, 268, 291 , 342, 394, 430, 431 and 451 of SEQ ID NO: 2 and/or 3.
  • the substitution at these positions is chosen from: N61 I, T67M, A72Y, S97N, S102M, I133T, T205Q, Q219S, W228H, W228M, S230F, S230G, S230N, S230R, S231 L, I239V, I239Y.
  • the variant has one or more substitutions corresponding to one of the following positions: 72, 133, 219, 228, 230, 231 , 239, 263, 268, and 451 of SEQ ID NO: 2 and/or 3.
  • the substitution at these positions is chosen from: A72Y, I133T, Q219S, W228H, W228M, S230R, S230F, S230G, S231 L, I239V, N263P, A268C, A268G, and S451 K of SEQ ID NO: 2 and/or 3.
  • the variant has at least one altered property and the at least one altered property is an increased specific activity as compared to the parent glucoamylase.
  • the variant of a glucoamylase parent comprises at least one of the following substitutions in the following positions in an amino acid sequence set forth in SEQ ID NO:2 or 3: TIOD/F/G/K/L/M/P/R/S; L14E/H; N15D/N; P23A/G; F59A/G; K60F/H; N61D/I/L/Q/V/W; R65A/C/G/1/K/M/S/V/Y; T67C/I/K/M/T; E68I/M/W; A72E/G/L/M/Q/R/W/Y; G73C/L ⁇ V; S97F/M/N/P/R/S/V/W/Y; L98H/M; A99C/L/M/N/P; S102A/C/I/L/M/N/R/V/W/Y; El 10Q/S/W; Ll 13E/N; K
  • the variant of a glucoamylase parent comprises one or more substitutions in the following positions in the amino acid sequence set forth in SEQ ID NO:2 or 3: 10, 15, 23, 42, 59, 60, 61 , 68, 72, 73, 97, 98, 99, 102, 1 14, 133, 140, 144, 147, 152, 153, 164, 182, 204, 205, 214, 216, 228, 229, 230, 231 , 236, 241 , 242, 263, 264, 265, 268, 269, 276, 284, 291 , 300, 301 , 303, 31 1 , 338, 342, 344, 346, 349, 359, 361 , 364, 375, 379, 382, 390, 391 , 393, 394, 410, 417, 430, 431 , 433, 436, 442, 443, 444, 448, and 451 or an equivalent position in a parent glucoa
  • the parent glucoamylase will have at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, and at least 99% sequence identity with SEQ ID NO: 2 or SEQ ID NO: 3.
  • the parent glucoamylase also shows structural identity with the glucoamylase of SEQ ID NOs: 2 and/or 3.
  • the parent glucoamylase will be a Trichoderma glucoamylase homologue.
  • the variant has one or more substitutions corresponding to one of the following positions: 10, 42, 68, 73, 97, 1 14, 153, 229, 231 , 236, 264, 291 , 301, 344, 361 , 364, 375, 417, and 433 of SEQ ID NO: 2 and/or 3.
  • the substitution at these positions is chosen from: TlOS, T42V, E68C, E68M, G73F, G73W, Kl 14M, Kl 14T, N153A, N153S, N153V, W228V, D236R, G361 D, G361 E, G361 P, G361Y,A364D, A364E, A364F, A364G, A364K, A365L, A365R, R433C, R433G, R433L, R433N, R433S, R433V, and I436H of SEQ ID NO: 2 and/or 3.
  • the variant has one or more substitutions corresponding to one of the following positions: 42, 68, 73, 1 14, 153, 236, 361 , and 364 of SEQ ID NOs: 2 and/or 3.
  • the substitution at these positions is chosen from: T42V, E68M, G73F, G73W, Kl 14T, N153S, N153V, D236R, G361 D, A364F, and A364L of SEQ ED NO: 2 and/or 3.
  • the variant has at least one altered property and the at least one altered property is an increased thermostability as compared to the parent glucoamylase.
  • the variant of a glucoamylase parent comprises one or more substitutions in the following positions in the amino acid sequence set forth in SEQ ID NOs:2 or 3: 10, 15, 59, 61 , 68, 72, 73, 97, 99, 102, 133, 140, 153, 182, 204, 205, 214, 228, 229, 230, 231 , 236, 241 , 242, 264, 265, 268, 275, 284, 291 , 300, 301 , 303, 31 1 , 338, 344, 346, 359, 361 , 364, 375, 370, 382, 391 , 393, 394, 410, 417, 430, 431 , 433, 444, 448, and 451 and/or an equivalent position in a parent glucoamylase (e.g., Trichoderma glucoamylase homologue).
  • a parent glucoamylase e.g., Trichoderma glucoamylase homologue
  • the parent glucoamylase will have at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, and at least 99% sequence identity with SEQ ID NO: 2 or SEQ ID NO: 3.
  • the parent glucoamylase will also have structural identity with the glucoamylase of SEQ ID NOs: 2 and/or 3.
  • the parent glucoamylase will be a Trichoderma glucoamylase homologue.
  • the variant will have at least one altered property as compared to the parent glucoamylase.
  • the variant has one or more substitutions corresponding to one of the following positions: 228, 230, 231 , 268, 291, 417, 433, and 451 of SEQ ID NOs: 2 and/or 3.
  • the substitution at these positions is chosen from: W228H, W228M, S230F, S230G, S230R, S231L, A268C, A268G, S291A, L417R, R433Y, and S451 K of SEQ ID NOs: 2 and/or 3.
  • the variant has at least one altered property and the at least one altered property is an increased thermostability or specific activity as compared to the parent glucoamylase. In some embodiments, the variant has both an increased thermostability and an increased specific activity as compared to the parent glucoamylase.
  • Glucoamylase variants of the invention may also include chimeric or hybrid glucoamylases with, for example a starch binding domain (SBD) from one glucoamylase and a catalytic domain and linker from another.
  • SBD starch binding domain
  • a hybrid glucoamylase can be made by swapping the SBD from AnGA with the SBD from TrGA, making a hybrid with the AnGA SBD and the TrGA catalytic domain and linker.
  • the SBD and linker from AnGA can be swapped for the SBD and linker of TrGA.
  • the variant glucoamylase exhibits increased thermostability as compared to the parent glucoamylase.
  • the altered property is increased specific activity compared to the parent glucoamylase. In some embodiments, the altered property is increased thermostability at lower temperatures as compared to the parent glucoamylase. In some embodiments, the altered property is both increased specific activity and increased thermostability as compared to the parent glucoamylase.
  • catalytic domain 5 includes the catalytic domain of the following parent glucoamylases Aspergillus awamori (AaGA) (SEQ ID NO:5); Aspergillus niger (AnGA) (SEQ ID NO:6); Aspergillus orzyae (AoGA) (SEQ ID NO:7), Humicola grisea (HgGA) (SEQ ID NO:8) and Hypocrea vinosa (HvGA) (SEQ ID NO:9).
  • AaGA Aspergillus awamori
  • AnGA Aspergillus niger
  • AoGA Aspergillus orzyae
  • HgGA Humicola grisea
  • HvGA Hypocrea vinosa
  • the variant glucoamylase will be derived from a parent glucoamylase which is an Aspergillus glucoamylase and the variant will include at least one substitution in a position equivalent to a position set forth in SEQ ID NO:2 or SEQ ID NO:3 and particularly in a position corresponding to: Tl O, L14, N15, P23, T42, P45, D46, F59, K60, N61 , R65, T67, E68, A72, G73, S97, L98, A99, S102, K108, EI l O, Ll 13, Kl 14, R122, Q124, R125, 1133, K140, N144, N145, Y 147, S 152, N 153, N 164, F 175, N 182, A204, T205, S214, V216, Q219, W228, V229, S230, S231 , D236, 1239, N240, T241 , N
  • the present invention also provides glucoamylase variants having at least one altered property (e.g., improved property) as compared to a parent glucoamylase and particularly to the TrGA.
  • at least one altered property e.g. improved property
  • the altered property is increased acid stability, increased thermal stability and/or increased specific activity.
  • the increased thermal stability is at higher temperatures.
  • the increased pH stability is at high pH. In further embodiments, the increased pH stability is at low pH.
  • the glucoamylase variants of the invention may also provide higher rates of starch hydrolysis at low substrate concentrations as compared to the parent glucoamylase.
  • the variant may have a higher Vmax or lower Km than a parent glucoamylase when tested under the same conditions.
  • the variant glucoamylase may have a higher Vmax at a temperature range of 25°C to 70°C (e.g. at 25°C to 35°C; 30°C - 35°C; 40°C to 50°C; at 50°C to 55°C and at 55°C to 62°C).
  • the Michaelis-Menten constant, Km and Vmax values can be easily determined using standard known procedures. Thermal stability (Thermostable variants):
  • the invention relates to a variant glucoamylase having altered thermal stability as compared to a parent (wild type).
  • Altered thermostability can be at increased temperatures or at decreased temperatures. Thermostability is measured as the % residual activity after incubation for 1 hour at 64 degree centigrade in NaAc buffer pH 4.5. Under these conditions TrGA has a residual activity of between about 15% and 44% due to day-to-day variation as compared to the initial activity before incubation.
  • variants with increased thermostability have a residual activity that is between at least 1% and at least 50% more than that of the parent (after incubation for 1 hour at 64 degrees centigrade in NaAc buffer pH 4.5), including 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%,48%, 49%, and 50% as compared to the initial activity before incubation.
  • a variant with increased thermal stability may have a residual activity of between about 16% and about 75%.
  • the glucoamylase variant will have improved thermostability such as retaining at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% enzymatic activity after exposure to altered temperatures over a given time period, for example, at least 60 minutes, 120 minutes, 180 minutes, 240 minutes, 300 minutes, etc.
  • the variant has increased thermal stability compared to the parent glucoamylase at selected temperatures in the range of 40 to 80°C, also in the range of 50 to 75°C and in the range of 60 to 70°C, and at a pH range of 4.0 to 6.0. In some embodiments, the thermostability is determined as described in the Examples. In some embodiments, the variant has increased thermal stability at lower temperature compared to the parent glucoamylase at selected temperature in the range of 20 to 50°C, including 35 to 45 and 30°C to 40°C.
  • variants having an improvement in thermostability include one or more deletions, substitutions or insertions and particularly substitutions in the following positions in the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:3: Tl O, Nl 5, P23, T42, F59, K60, N61 , E68, A72, G73, S97, L98, A99, S102, Kl 14, 1133, K 140, Nl 44, Y147, S152, N 153, N164, N 182, A204, T205, S214, V216, W228, V229, S230, S231 , D236, T241 , N242, N263, L264, G265, A268, G269, D276, V284, S291 , P300, A301 , A303, A31 1 , V338, T342, S344, T346, A349, V359, G361 , A364, T375.
  • the parent glucoamylase will be a Trichoderma glucoamylase homologue and in further embodiments, the parent glucoamylase will have at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% and at least 98% sequence identity to SEQ ID NOs:2 or 3. In some embodiments, the parent glucoamylase will also have structural identity to SEQ ID NOs: 2 and/or 3.
  • the variant having increased thermostability has a substitution in at least one of the positions: 10, 42, 68, 73, 97, 153, 229, 231 , 236, 264, 291 , 301 , 344, 361 , 364, 375, and/or 417 of SEQ ID NO: 2 and/or 3.
  • the variant having thermostability has a substitution in at least one of the positions: 42, 68, 73, 153, 236, 344, 361 , 364, and 365 of SEQ ID NO: 2 or SEQ ID NO:3.
  • Specific activity [127] As used herein, specific activity is the activity of the glucoamylase per mg of protein. Activity was determined using the ethanol assay.
  • the screening identified variants having a Performance Index (PI) >1.0 compared to the parent TrGA PI.
  • the PI is calculated from the specific activities (activity/mg enzyme) of the wildtype (WT) and the variant enzymes. It is the quotient "Variant-specific activity/WT- specific activity" and can be a measure of the increase in specific activity of the variant.
  • a PI of 2 should be about 2 fold better than WT
  • the invention relates to a variant glucoamylase having altered specific activity as compared to a parent or wildtype glucoamylase. In some embodiments, the altered specific activity is increased specific activity.
  • Increased specific activity can be defined as an increased performance index of greater than or equal to about 1, including greater than or equal to about 1.1 , 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, and 2.
  • the increased specific activity is from about 1.0 to about 5.0, including 1.1 , 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1 , 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, and 4.9.
  • the variant has an at least 1 fold higher specific activity than the parent glucoamylase, including at least 1.1 fold, 1.2 fold, 1.3 fold, 1.4 fold, 1.5 fold, 1.6 fold, 1.7 fold, 1.8 fold, 1.9 fold, 2 fold, 2.2 fold, 2.5 fold, 2.7 fold, 2.9 fold, 3 fold, 4 fold, and 5 fold.
  • variants having an improvement in specific activity include one or more deletions, substitutions or insertions in the following positions in the amino acid sequence set forth in SEQ ID NO:2 and/or 3: Tl O, L14, N15, P23, F59, K60, N61 , T67, E68, A72, G73, S97, L98, A99, S102, El 10, Ll 13, 1133, K140, N144, N145, Y147, S152, N153, N164, N182, A204, T205, S214, V216, Q219, W228, V229, S230, S231 , D236, 1239, T241 , N242, N263, L264, G265, A268, G269, D276, V284, S291, P300, A301, A31 1, V338, T342, S344, T346, A349, V359, G361, A364, T375, N379, S382, S390, E391,
  • variants of the invention having improved specific activity include a substitution in the following positions in the amino acid sequence set forth in SEQ ID NO: 2 or 3 : 61 , 67, 72, 97, 102, 133, 205, 219, 228, 230, 231 , 239, 263, 268, 291 , 342, 394, 430, 431 and 451 and/or an equivalent position in a parent glucoamylase.
  • the parent glucoamylase will comprise a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 95% sequence identity to the sequence of SEQ ID NO:2 or 3.
  • the parent glucoamylase will also have structural identity to SEQ ID NO: 2 and/or 3.
  • the variant having increased specific activity has a substitution in at least one of the positions: 72, 133, 219, 228, 230, 231 , 239, 263, 268, and 451 of SEQ ID NO: 2 and/or 3.
  • the invention relates to a variant glucoamylase having both altered thermostability and altered specific activity as compared to a parent (e.g.,wildtype).
  • the altered specific activity is an increased specific activity.
  • the altered thermostability is an increased thermostability at high temperatures (e.g., at temperatures above 80°C) as compared to the parent glucoamylase.
  • variants with an increased thermostability and increased specific activity include one or more deletions, substitutions or insertions and substitutions in the following positions in the amino acid sequence set forth in SEQ ID NOs:2 or 3: Tl O, N15, F59, N61 , E68, A72, G73, S97, A99, S102, 1133, K140, N153, N182, A204, T205, S214, W228, V229, S230, S231 , D236, T241.
  • the parent glucoamylase will be a Trichoderma glucoamylase homologue and in further embodiments, the parent glucoamylase will have at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% and at least 98% sequence identity to SEQ ID NO:2 or 3. In some embodiments, the parent glucoamylase will also have structural identity to SEQ ID NO: 2 and/or 3. In some embodiments, the variant having increased thermostability and specific activity has a substitution in at least one of the positions: 228, 230, 231 , 268, 291 , 417, 433, and 451 of SEQ ID NO: 2 and/or 3.
  • the present invention also relates to isolated polynucleotides encoding a variant glucoamylase of the invention.
  • the polynucleotides may be prepared by established techniques known in the art.
  • the polynucleotides may be prepared synthetically, such as by an automatic DNA synthesizer.
  • the DNA sequence may be of mixed genomic (or cDNA) and synthetic origin prepared by ligating fragments together.
  • the polynucleotides may also be prepared by polymerase chain reaction (PCR) using specific primers.
  • PCR polymerase chain reaction
  • DNA may also be synthesized by a number of commercial companies such as Geneart AG, Regensburg, Germany.
  • the present invention also provides isolated polynucleotides comprising a nucleotide sequence (i) having at least 50% identity to SEQ ID NO:4, including at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, and at least 99%, or (ii) being capable of hybridizing to a probe derived from the nucleotide sequence set forth in SEQ ID NO:4, under conditions of intermediate to high stringency, or (iii) being complementary to a nucleotide sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO:4.
  • Probes useful according to the invention may include at least 50, 100, 150, 200, 250, 300 or more contiguous nucleotides of SEQ ID NO:4.
  • the encoded polypeptide also has structural identity to SEQ ID NOs: 2 and/or 3.
  • the present invention further provides isolated polynucleotides that encode variant glucoamylases which comprise an amino acid sequence comprising at least 50%, at least 60%, at least 70%, at least 80% , at least 90%, at least 93%, at least 95%, at least 97%, at least 98%, or at least 99% amino acid sequence identity to SEQ ID NO:2. Additionally, the present invention provides expression vectors comprising any of the polynucleotides provided above.
  • the present invention also provides fragments (i.e., portions) of the DNA encoding the variant glucoamylases provided herein. These fragments find use in obtaining partial length DNA fragments capable of being used to isolate or identify polynucleotides encoding mature glucoamylase enzymes described herein from filamentous fungal cells (e.g., Trichoderma, Aspergillus, Fusarium, Penicillium, and Humicola), or a segment thereof having glucoamylase activity. In some embodiments, fragments of the DNA may comprise at least 50, 100, 150, 200, 250 300 or more contiguous nucleotides.
  • portions of the DNA provided in SEQ ID NO:4 find use in obtaining parent glucoamylase and particularly Trichoderma glucoamylase homologues from other species, such as filamentous fungi which encode a glucoamylase.
  • a DNA construct comprising a polynucleotide as described above encoding a variant glucoamylase encompassed by the invention and operably linked to a promoter sequence is assembled to transfer into a host cell.
  • the DNA construct may be introduced into a host cell using a vector.
  • the vector may be any vector which when introduced into a host cell is stably introduced.
  • the vector is integrated into the host cell genome and is replicated.
  • Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, phage particles, cassettes and the like.
  • the vector is an expression vector that comprises regulatory sequences operably linked to the glucoamylase coding sequence.
  • suitable expression and/or integration vectors are provided in Sambrook et ah, (1989) supra, and Ausubel (1987) supra, and van den Hondel et ⁇ /.
  • Suitable plasmids for use in bacterial cells include pBR322 and pUC19 permitting replication in E.coli and pE194 for example permitting replication in Bacillus.
  • Other specific vectors suitable for use in E. coli host cells include vectors such as pFB6, pBR322, pUCl 8, pUCl 00, pDONRTM201 , pDONRTM221 , pENTRTM, pGEM ® 3Z and pGEM ® 4Z.
  • Specific vectors suitable for use in fungal cells include pRAX, a general purpose expression vector useful in Aspergillus, pRAX with a g/aA promoter, and in Hypocrea/Trichoderma includes pTrex3g with a cbh ⁇ promoter.
  • the promoter shows transcriptional activity in a bacterial or a fungal host cell and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
  • the promoter may be a mutant, a truncated and/or a hybrid promoter.
  • the above-mentioned promoters are known in the art.
  • suitable promoters useful in fungal cells and particularly filamentous fungal cells such as Trichoderma or Aspergillus cells include such exemplary promoters as the T. reesei promoters cbh ⁇ , cbh2, egl1 , egl2, eg5, xln ⁇ and xlnl.
  • Other examples of useful promoters include promoters from A. awamori and A. niger glucoamylase genes (glaA) ⁇ See, Nunberg et ai, (1984) MoI. Cell Biol. 4:2306-2315 and Boel et al., (1984) EMBO J. 3: 1581-1585), A.
  • TPI riose phosphate isomerase
  • S. cerevisiae the promoter from Aspergillus nidulans acetamidase genes and Rhizomucor miehei lipase genes.
  • suitable promoters useful in bacterial cells include those obtained from the E. coli lac operon; Bacillus licheniformis alpha amylase gene (amyL), B. stearothermophilus amylase gene (amyS); Bacillus subtilis xylA and xylB genes, the beta-lactamase gene, and the tac promoter.
  • the promoter is one that is native to the host cell.
  • the promoter when T. reesei is the host, the promoter is a native T. reesei promoter. In other embodiments, the promoter is one that is heterologous to the fungal host cell. In some embodiments, the promoter will be the promoter of a parent glucoamylase (e.g., the TrGA promoter).
  • the DNA construct includes nucleic acids coding for a signal sequence, that is, an amino acid sequence linked to the amino terminus of the polypeptide which directs the encoded polypeptide into the cell's secretory pathway.
  • the 5' end of the coding sequence of the nucleic acid sequence may naturally include a signal peptide coding region which is naturally linked in translation reading frame with the segment of the glucoamylase coding sequence which encodes the secreted glucoamylase or the 5' end of the coding sequence of the nucleic acid sequence may include a signal peptide which is foreign to the coding sequence.
  • the DNA construct includes a signal sequence that is naturally associated with a parent glucoamylase gene from which a variant glucoamylase has been obtained.
  • the signal sequence will be the sequence depicted in SEQ ID NO: 1 or a sequence having at least 90%, at least 94% and at least 98% sequence identity thereto.
  • Effective signal sequences may include the signal sequences obtained from other filamentous fungal enzymes, such as from Trichoderma (T. reesei glucoamylase,), Humicola (H. insolens cellulase or H. grisea glucoamylase), Aspergillus (A. niger glucoamylase and A. oryzae TAKA amylase), and Rhizopus.
  • a DNA construct or vector comprising a signal sequence and a promoter sequence to be introduced into a host cell are derived from the same source.
  • the native glucoamylase signal sequence of a Trichoderma glucoamylase homologue such as a signal sequence from a Hypocrea strain may be used.
  • the expression vector also includes a termination sequence. Any termination sequence functional in the host cell may be used in the present invention. In some embodiments, the termination sequence and the promoter sequence are derived from the same source. In another embodiment, the termination sequence is homologous to the host cell. Useful termination sequences include termination sequences obtained from the genes of Trichoderma reesei cbh ⁇ ; A. niger or A. awamori glucoamylase (Nunberg et al. (1984) supra, and Boel et al., (1984) supra), Aspergillus nidulans anthranilate synthase, Aspergillus oryzae TAKA amylase, or A.
  • an expression vector includes a selectable marker.
  • selectable markers include ones which confer antimicrobial resistance (e.g., hygromycin and phleomycin).
  • Nutritional selective markers also find use in the present invention including those markers known in the art as amdS (acetamidase), argB (ornithine carbamoyltransferase) and pyrG (orotidine-5 'phosphate decarboxylase).
  • Markers useful in vector systems for transformation of Trichoderma are known in the art (See, e.g., Finkelstein, chapter 6 in BIOTECHNOLOGY OF FILAMENTOUS FUNGI, Finkelstein et al. (1992) Eds. Butterworth-Heinemann, Boston, MA; Kinghorn et al. (1992) APPLIED MOLECULAR GENETICS OF FILAMENTOUS FUNGI, Blackie Academic and Professional, Chapman and Hall, London; Berges and Barreau (1991) Curr. Genet. 19:359 - 365; and van Hartingsveldt et al., (1987) MoI. Gen. Genet. 206:71 - 75).
  • the selective marker is the amdS gene, which encodes the enzyme acetamidase, allowing transformed cells to grow on acetamide as a nitrogen source.
  • A. nidulans amdS gene as a selective marker is described in Kelley et al., (1985) EMBO J. 4:475 - 479 and Penttila et al., (1987) Gene 61 : 155-164.
  • the present invention also relates to host cells comprising a polynucleotide encoding a variant glucoamylase of the invention.
  • the host cells are chosen from bacterial, fungal, plant and yeast cells.
  • the term host cell includes both the cells, progeny of the cells and protoplasts created from the cells which are used to produce a variant glucoamylase according to the invention.
  • the host cells are fungal cells and preferably filamentous fungal host cells.
  • filamentous fungi refers to all filamentous forms of the subdivision Eumycotina (See, Alexopoulos, C. J. (1962), INTRODUCTORY MYCOLOGY, Wiley, New York).
  • filamentous fungal parent cell may be a cell of a species of, but not limited to, Trichoderma, (e.g., Trichoderma reesei, the asexual morph of Hypocrea jecorina, previously classified as T.
  • the host cells will be gram-positive bacterial cells.
  • Non-limiting examples include strains of Streptomyces, (e.g., S. lividans , S. coelicolor and S. griseus) and Bacillus.
  • the genus Bacillus ' includes all species within the genus "Bacillus,' ' ' as known to those of skill in the art, including but not limited to B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B.
  • the host cell is a gram— negative bacterial strain, such as E. coli or
  • the host cells may be yeast cells such as Saccharomyces sp., Schizosaccharomyces sp., Pichia sp., or Candida sp.
  • the host cell will be a genetically engineered host cell wherein native genes have been inactivated, for example by deletion in bacterial or fungal cells. Where it is desired to obtain a fungal host cell having one or more inactivated genes known methods may be used (e.g. methods disclosed in U.S. Patent No. 5,246,853, U.S. Patent No. 5,475,101 and WO 92/06209).
  • Gene inactivation may be accomplished by complete or partial deletion, by insertional inactivation or by any other means which renders a gene nonfunctional for its intended purpose (such that the gene is prevented from expression of a functional protein).
  • the host cell when the host cell is a Trichoderma cell and particularly a T. reesei host cell, the cbh ⁇ , cbhl, egl ⁇ and egl2 genes will be inactivated and/or deleted.
  • Exemplary Trichoderma reesei host cells having quad-deleted proteins are set forth and described in USP 5,847,276 and WO 05/001036.
  • the host cell is a protease deficient or protease minus strain. Transformation of host cells:
  • Transformation methods for Bacillus are disclosed in numerous references including Anagnostopoulos C and J. Spizizen (1961) J. Bacteriol. 81 :741 - 746 and WO 02/14490.
  • the preparation of Trichoderma sp. for transformation involves the preparation of protoplasts from fungal mycelia (See, Campbell et al., (1989) Curr. Genet. 16:53-56; Pentilla et al., (1987) Gene 61 : 155 - 164).
  • Agrobacterium tumefaciens-mediated transformation of filamentous fungi is known (See, de Groot et al., (1998) Nat. Biotechnol. 16:839 - 842).
  • genetically stable transformants are constructed with vector systems whereby the nucleic acid encoding the variant glucoamylase is stably integrated into a host strain chromosome. Transformants are then purified by known techniques.
  • the host cells are plant cells, such as cells from a monocot plant (e.g. corn, wheat and sorghum) or cells from a dicot plant (e.g. soybean).
  • a monocot plant e.g. corn, wheat and sorghum
  • a dicot plant e.g. soybean
  • Methods for making DNA constructs useful in transformation of plants and methods for plant transformation are known. Some of these methods include Agrobacterium tumefaciens mediated gene transfer; microprojectile bombardment, PEG mediated transformation of protoplasts, electroporation and the like.
  • USP 6,803,499, USP 6,777,589 Fromm et al (1990) Biotechnol. 8:833-839
  • the present invention further relates to methods of producing the variant glucoamylases, which comprises transforming a host cell with an expression vector comprising a polynucleotide encoding a variant glucoamylase according to the invention, culturing the host cell under conditions suitable for expression and production of the variant glucoamylase and optionally recovering the variant glucoamylase.
  • the host cells are cultured under suitable conditions in shake flask cultivation, small scale or large scale fermentations (including continuous, batch and fed batch fermentations ) in laboratory or industrial fermentors, with suitable medium containing physiological salts and nutrients (See, e.g., Pourquie, J. et al., BIOCHEMISTRY AND GENETICS OF CELLULOSE DEGRADATION, eds. Aubert, J. P. et al., Academic Press, pp. 71 -86, 1988 and Ilmen, M. et al, (1997) Appl. Environ. Microbiol. 63:1298-1306).
  • Yeast Malt Extract e.g., YM
  • Luria Bertani LB
  • SD Sabouraud Dextrose
  • a glucoamylase coding sequence is under the control of an inducible promoter
  • the inducing agent e.g., a sugar, metal salt or antimicrobial
  • the medium is added to the medium at a concentration effective to induce glucoamylase expression.
  • the present invention relates to methods of producing the variant glucoamylase in a plant host comprising transforming a plant cell with a vector comprising a polynucleotide encoding a glucoamylase variant according to the invention and growing the plant cell under conditions suitable for the expression and production of the variant.
  • assays are carried out to evaluate the expression of a variant glucoamylase by a cell line that has been transformed with a polynucleotide encoding a variant glucoamylase encompassed by the invention.
  • the assays can be carried out at the protein level, the RNA level and/or by use of functional bioassays particular to glucoamylase activity and/or production. Some of these assays include Northern blotting, dot blotting (DNA or RNA analysis), RT-PCR (reverse transcriptase polymerase chain reaction), in situ hybridization using an appropriately labeled probe (based on the nucleic acid coding sequence) and conventional Southern blotting and autoradiography. [161] In addition, the production and/or expression of a variant glucoamylase may be measured in a sample directly, for example, by assays directly measuring reducing sugars such as glucose in the culture medium and by assays for measuring glucoamylase activity, expression and/or production.
  • glucoamylase activity may be assayed by the 3,5-dinitrosalicylic acid (DNS) method (See, Goto et al., (1994) Biosci. Biotechnol. Biochem. 58:49 - 54).
  • protein expression is evaluated by immunological methods, such as immunohistochemical staining of cells, tissue sections or immunoassay of tissue culture medium, (e.g., by Western blot or ELISA).
  • immunoassays can be used to qualitatively and quantitatively evaluate expression of a glucoamylase. The details of such methods are known to those of skill in the art and many reagents for practicing such methods are commercially available.
  • the glucoamylases of the present invention may be recovered or purified from culture media by a variety of procedures known in the art including centrifugation, filtration, extraction, precipitation and the like.
  • the variant glucoamylases of the invention may be used in enzyme compositions including but not limited to starch hydrolyzing and saccharifying compositions, cleaning and detergent compositions (e.g., laundry detergents, dish washing detergents, and hard surface cleaning compositions), alcohol fermentation compositions, and in animal feed compositions. Further the variant glucoamylases may be used in baking applications, such as bread and cake production, brewing, healthcare, textile, environmental waste conversion processes, biopulp processing, and biomass conversion applications.
  • an enzyme composition comprising a variant glucoamylase encompassed by the invention will be optionally used in combination with any one or combination of the following enzymes - alpha amylases, proteases, pullulanases, isoamylases, cellulases, hemicellulases, xylanases, cyclodextrin glycotransferases, lipases, phytases, laccases, oxidases, esterases, cutinases, xylanases, granular starch hydrolyzing enzymes and other glucoamylases.
  • the enzyme composition will include an alpha amylase such as fungal alpha amylases (e.g. Aspergillus sp.) or bacterial alpha amylases (e.g. Bacillus sp. such as B. stearothermophilus, B. amyloliquefaciens and B. licheniformis) and variants and hybrids thereof.
  • the alpha amylase is an acid stable alpha amylase.
  • the alpha amylase is Aspergillus kawachi alpha amylase (AkAA), see US 7,037,704.
  • the enzyme composition will include an acid fungal protease.
  • the acid fungal protease is derived from a Trichoderma sp and may be any one of the proteases disclosed in US 2006/015342, published 7/13/2006( e.g. SEQ ID NO: 10).
  • the enzyme composition will include a phytase (e.g., a Buttiauxiella spp. or variant thereof (e.g., see PCT patent publication WO 2006/043178).
  • the variant glucoamylases of the invention may be combined with other glucoamylases.
  • the glucoamylases of the invention will be combined with one or more glucoamylases derived from strains of Aspergillus or variants thereof, such as A. oryzae, A. niger, A. kawachi, and A. awamori; glucoamylases derived from strains of Humicola or variants thereof, particularly H.
  • grisea such as the glucoamylase having at least 90%, 93%, 95%, 96%, 97%, 98% and 99% sequence identity to SEQ ID NO: 3 disclosed in WO 05/052148; glucoamylases derived from strains of Talaromyces or variants thereof, particularly T. emersoni ⁇ , glucoamylases derived from strains of Athelia and particularly A. rolfsii; glucoamylases derived from strains of Penicillium, particularly P. chrysogenum. Uses:
  • the variant glucoamylases may be used for starch conversion processes, and particularly in the production of dextrose for fructose syrups, specialty sugars and in alcohol and other end-product (e.g. organic acid, ascorbic acid, and amino acids) production from fermentation of starch containing substrates (G.M.A van Beynum et al., Eds. (1985) STARCH CONVERSION TECHNOLOGY, Marcel Dekker Inc. NY).
  • Dextrins produced using variant glucoamylase compositions of the invention may result in glucose yields of at least 80%, at least 85%, at least 90% and at least 95%.
  • Production of alcohol from the fermentation of starch substrates using glucoamylases encompassed by the invention may include the production of fuel alcohol or potable alcohol.
  • the production of alcohol will be greater when the variant glucoamylase is used under the same conditions as the parent glucoamylase.
  • the production of alcohol will be between about 0.5% and 2.5% better, including but not limited to 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%. 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, and 2.4% more alcohol than the parent glucoamylase.
  • the variant glucoamylases of the invention will find use in the hydrolysis of starch from various plant-based substrates, which are used for alcohol production.
  • the plant-based substrates will include corn, wheat, barley, rye, milo, rice, sugar cane, potatoes and combinations thereof.
  • the plant-based substrate will be fractionated plant material, for example a cereal grain such as corn, which is fractionated into components such as fiber, germ, protein and starch (endosperm) (USP 6,254,914 and USP 6,899,910).
  • the alcohol will be ethanol.
  • alcohol fermentation production processes are characterized as wet milling or dry milling processes.
  • the variant glucoamylase will be used in a wet milling fermentation process and in other embodiments the variant glucoamylase will find use in a dry milling process.
  • Dry grain milling involves a number of basic steps, which generally include: grinding, cooking, liquefaction, saccharification, fermentation and separation of liquid and solids to produce alcohol and other co-products.
  • Plant material and particularly whole cereal grains, such as corn, wheat or rye are ground. In some cases the grain may be first fractionated into component parts.
  • the ground plant material may be milled to obtain a coarse or fine particle.
  • the ground plant material is mixed with liquid (e.g. water and/or thin stillage) in a slurry tank.
  • the slurry is subjected to high temperatures (e.g. 90°C to 105°C or higher) in a jet cooker along with liquefying enzymes (e.g.
  • alpha amylases to solublize and hydrolyze the starch in the grain to dextrins.
  • the mixture is cooled down and further treated with saccharifying enzymes, such as glucoamylases encompassed by the instant invention, to produce glucose.
  • saccharifying enzymes such as glucoamylases encompassed by the instant invention.
  • the mash containing glucose may then be fermented for approximately 24 to 120 hours in the presence of fermentation microorganisms, such as ethanol producing microorganism and particularly yeast ⁇ Saccharomyces spp).
  • the solids in the mash are separated from the liquid phase and alcohol such as ethanol and useful co-products such as distillers' grains are obtained.
  • the saccharification step and fermentation step are combined and the process is referred to as simultaneous saccharification and fermentation or simultaneous saccharification, yeast propagation and fermentation.
  • the variant glucoamylase is used in a process for starch hydrolysis wherein the temperature of the process is between 30°C and 75°C, in some embodiments, between 40°C and 65°C. In some embodiments, the variant glucoamylase is used in a process for starch hydrolysis at a pH of between pH 3.0 and pH 6.5.
  • the fermentation processes in some embodiments include milling of a cereal grain or fractionated grain and combining the ground cereal grain with liquid to form a slurry which is then mixed in a single vessel with a variant glucoamylase according to the invention and optionally other enzymes such as, but not limited to, alpha amylases, other glucoamylases, phytases, proteases, pullulanases, isoamylases or other enzymes having granular starch hydrolyzing activity and yeast to produce ethanol and other co-products (See e.g., USP 4,514,496, WO 04/081 193 and WO 04/080923).
  • the invention pertains to a method of saccharifying a liquid starch solution, which comprises an enzymatic saccharification step using a variant glucoamylase of the invention.
  • the present invention also provides an animal feed composition or formulation comprising at least one variant glucoamylase encompassed by the invention.
  • Methods of using a glucoamylase enzyme in the production of feeds comprising starch are provided in WO 03/049550 (herein incorporated by reference in its entirety). Briefly, the glucoamylase variant is admixed with a feed comprising starch. The glucoamylase is capable of degrading resistant starch for use by the animal.
  • pNPG glucoamylase activity assay for 96-well microtiter plates [178] The reagent solutions were: NaAc buffer (200 mM sodium acetate buffer pH 4.5); Substrate (50 mM p-nitrophenyl- ⁇ -D-glucopyranoside (Sigma N- 1377) in NaAc buffer (0.3 g/20ml)) and stop solution (800 mM glycine-NaOH buffer pH 10).
  • the diluted sample was equally divided over 2 MTPs.
  • One MTP (initial plate) was incubated for 1 hr at 4°C and the other MTP (residual plate) was incubated at 64°C (Thermolab systems iEMS Incubator/Shaker HT) for 1 hr.
  • the residual plate was chilled for 10 min on ice. Activity was measured of both plates using the ethanol screening assay described below. 60 ⁇ l of the initial plate or residual plate was added to 120 ⁇ l 4% soluble corn starch and incubated for 2 hrs at 32°C 900 rpm (Thermolabsystems iEMS Incubator/Shaker HT). [180] Thermal stability was calculated as % residual activity as follows:
  • the PI of a variant is the quotient "Variant-residual activity/WT-residual activity.”
  • the PI of WT is 1.0 and a variant with a PI > 1.0 has a specific activity that is greater than WT.
  • Caliper protein determination [183] Data analysis and calculation of performance index of ethanol application assay.
  • Protein levels were measured using a microfiuidic electrophoresis instrument (Caliper Life Sciences, Hopkinton, MA, USA).
  • the microfiuidic chip and protein samples were prepared according to the manufacturer's instructions (LABCHIP® HT Protein Express, P/N 760301). Culture supernatants were prepared and stored in 96-well microtiter plates at -20°C until use, when they were thawed by warming in a 37°C incubator for 30 minutes.
  • the calibration ladders are checked for correctness of the peak pattern. If the calibration ladder which was associated with the run did not suffice, it was replaced by a calibration ladder of an adjacent run.
  • the default settings of the global peak find option of the caliper software were used. The peak of interest was selected at 75 kDA +/-10%.
  • the PI of a variant is the quotient "Variant-specific activity/WT-specific activity.”
  • the PI of WT is 1.0 and a variant with a PI > 1.0 had a specific activity that is greater than WT.
  • Hexokinase cocktail 10 - 15 minutes prior to use, 90 ml water was added to a BoatIL container glucose HK Rl (IL test glucose (HK) kit, Instrument Laboratory # 182507-40) and gently mixed. 100 ⁇ l of Hexokinase cocktail was added to 85 ⁇ l of dH 2 O. 15 ⁇ l of sample was added to the mixtures and incubated for 10 minutes in the dark at room temperature. Absorbance was read at 340 nm in a MTP- reader. Glucose concentrations were calculated according to a glucose (0 - 2 mg/ml) standard curve.
  • ethanol screening assay [189] 8% stock solution: 8 g of soluble corn starch (Sigma #S4180) was suspended in 40 ml dH 2 O at room temperature. 50 ml of boiling dH 2 O was added to the slurry in a 250 ml flask and cooked for 5 minutes. The starch solution was cooled to 25°C and the volume adjusted to 100 ml with dH 2 O. [190] Stop solution: 800 mM Glycine-NaOH buffer, pH 10. [191] 4% (m/v) soluble starch working solution: stock solution was diluted (1 : 1) with 100 mM sodium acetate buffer pH 3.7.
  • Example 1 Construction of TrGA site evalution libraries (SELs) in the pTTT vector for expression in Trichoderma reesei
  • a Trichoderma reesei cDNA sequence (SEQ ID NO: 4) was cloned into pDONRTM201 via the Gateway® BP recombination reaction (Invitrogen, Carlsbad, CA, USA) resulting in the entry vector pDONR-TrGA (Fig. 2).
  • the cDNA sequence (SEQ ID NO:4) encodes the TrGA signal peptide, the pro- sequence, and the mature protein, including the catalytic domain, linker region and starch binding domain (SEQ ID NO: 1).
  • SEQ ID NO:4 and SEQ ID NO: 1 are shown in Figure I B and IA.
  • Figure 1C illustrates the precursor and mature protein TrGA domains.
  • TrGA coding sequence SEQ ID NO:4
  • the expression vector contained the T. reesei cbhl-derived promoter and terminator regions which allowed for strong inducible expression of a gene of interest.
  • the vector also contained the Aspergillus nidulans amdS selective marker which allowed for growth of the transformants on acetamide as a sole nitrogen source.
  • the expression vector also contained T.
  • telomere regions which allowed for non-chromosomal plasmid maintenance in a fungal cell.
  • the cbhl promoter and terminator regions were separated by the chloramphenicol resistance gene, Cm R , and the lethal E. coli gene, ccdB, flanked by the bacteriophage lambda-based specific recombination sites attRl , attR2.
  • This configuration allowed for direct selection of recombinants containing the TrGA gene under control of the cbhl regulatory elements in the right orientation via the GATEWAY® LR recombination reaction.
  • the final expression vector pTTT-TrGA is shown in Figure 4.
  • each SEL library started with two independent PCR amplifications on the pDONR-TrGA entry vector: one using the Gateway F (pDONR201 - FW) and a specific mutagenesis primer R (Table 2), and the other - the Gateway primer R (pDONR201 - RV) and a specific mutagenesis primer F (Table 2).
  • High fidelity PHUSION DNA polymerase (Finnzymes OY, Espoo, Finland) was used in a PCR amplification reaction including 0.2 ⁇ M primers. The reactions were carried out for 25 cycles according to the protocol provided by Finnzymes.
  • pTTT-TrGA with mutations at the desired position were selected by plating bacteria on 2xYT agar plates (16 g/L Bacto Tryptone (Difco), 10 g/L Bacto Yeast Extract (Difco), 5 g/L NaCl, 16 g/L Bacto Agar (Difco)) with lOO ⁇ g/ml ampicillin.
  • the SELs were transformed into T. reesei using the PEG protoplast method.
  • the E.coli clones of the SELs confirmed by sequence analysis were grown overnight at 37°C in deep well microtiter plates (Greiner Art. No. 780271 ) containing 1.200 ⁇ l of 2xYT medium with ampicillin (100 ⁇ g/ml) and kanamycin (50 ⁇ g/ml).
  • Plasmid DNAs were isolated from the cultures using CHEMAGIC® Plasmid Mini Kit (Chemagen - Biopolymer Technologie AG, Baesweiler, Germany) and were transformed individually into a T.
  • spores were grown for 16-24 hours at 24°C in Trichoderma Minimal Medium (MM) (20g/L glucose, 15g/L KH 2 PO 4 , pH 4.5, 5g/L (NRO 2 SO 4 , 0.6g/L MgSO 4 x7H 2 O, 0.6 g/L CaCl 2 x2H 2 O, 1 ml of I OOOX T.
  • MM Trichoderma Minimal Medium
  • transformation method was scaled down 10 fold.
  • transformation mixtures containing up to 600 ng of DNA and l-5x 10 5 protoplasts in a total volume of 25 ⁇ l were treated with 200 ml of 25% PEG solution, diluted with 2 volumes of 1.2M sorbitol solution, mixed with 3% selective top agarose MM with acetamide (the same Minimal Medium as mentioned above but (NHi) 2 SO 4 was substituted with 20 mM acetamide) and poured onto 2% selective agarose with acetamide either in 24 well microtiter plates or in a 20x20 cm Q-tray divided in 48 wells. The plates were incubated at 28°C for 5 to 8 days.
  • Spores from the total population of transformants regenerated on each individual well were harvested from the plates using a solution of 0.85% NaCl, 0.015% Tween 80. Spore suspensions were used to inoculate fermentations in 96 wells MTPs. In the case of 24 well MTPs, an additional plating step on a fresh 24 well MTP with selective acetamide MM was introduced in order to enrich the spore numbers.
  • Example 3 Fermentation of T. reesei transformants expressing TrGA variants in a MTP format [200] The tranformants were fermented and the supernatants containing the expressed variant TrGA proteins were tested for various properties. In brief, 96 well filter plates (Corning Art.No.
  • LD-GSM medium 5.0 g/L (NH 4 ) 2 SO 4 , 33 g/L 1 ,4-Piperazinebis(propanesulfonic acid), pH 5.5, 9.0 g/L Casamino acids, 1.0 g/L KH 2 PO 4 , 1.0 g/L CaCl 2 x2H 2 O, 1.0 g/L MgSO 4 x7H 2 O, 2.5 ml/L of I OOOX T. reesei trace elements, 20 g/L Glucose, 10 g/L Sophorose) were inoculated in quadruplicate with spore suspensions of T.
  • LD-GSM medium 5.0 g/L (NH 4 ) 2 SO 4 , 33 g/L 1 ,4-Piperazinebis(propanesulfonic acid), pH 5.5, 9.0 g/L Casamino acids, 1.0 g/L KH 2 PO 4 , 1.0 g/
  • TrGA variants more than 10 4 spores per well.
  • the plates were incubated at 28°C with 230 rpm shaking and 80% humidity for 6 days. Culture supernatants were harvested by vacuum filtration. The supernatants were used in different assays for screening of variants with improved properties.
  • TrGA producing transformants were initially pregrown in 250 ml shake flasks containing 30 ml of Proflo medium.
  • Proflo medium contained: 30 g/L ⁇ -lactose, 6.5 g/L (NH 4 ) 2 SO 4 , 2 g/L KH 2 PO 4 , 0.3 g/L MgSO 4 x7H 2 O, 0.2 g/L CaCl 2 x2H 2 O, 1 ml/L IOOOX trace element salt solution as mentioned above, 2 ml/L 10% Tween 80, 22.5 g/L ProFlo cottonseed flour (Traders protein, Memphis, TN), 0.72 g/L CaCO 3 .
  • Lactose Defined Medium was as follows: 5 g/L (NH t ) 2 SO 4 , 33 g/L 1 ,4-Piperazinebis (propanesulfonic acid) buffer, pH 5.5, 9 g/L casamino acids, 4.5 g/L KH 2 PO 4 , 1.0 g/L MgSO 4 x7H 2 O, 5 ml/L Mazu DF60-P antifoam (Mazur Chemicals, IL), 1 ml/I of 100OX trace element solution.
  • the parent TrGA molecule had a residual activity between 15 and 44 % (day-to-day variation) under the conditions described.
  • the performance index was calculated based on the TrGA thermostability of the same batch.
  • Variants which had a thermal stability performance index (PI) of more than 1.0 are shown in the following Table 3.
  • Table 3 includes those variants that, when tested, showed an increased performance index over the parent glucoamylase. These included the following sites: 10, 42, 59, 60, 61 , 68, 72, 73, 97, 98, 99, 102, 1 14, 133, 140, 144, 147, 152, 153, 164, 182, 204, 205, 214, 216, 228, 229, 230, 231 , 236, 241 , 242, 263, 264, 265, 268, 269, 276, 284, 291 , 300, 301 , 303, 31 1 , 338, 342, 344, 346, 349, 359, 361 , 364, 375, 379, 382, 390, 391 , 393, 394, 410, 417, 430, 431 , 433, 436, 442, 443, 444, 448, and 451.
  • Variants were tested in an ethanol screening assay using the assays described above.
  • Table 4 shows the results of the screening assay for variants with a Performance Index (PI) >1 .0 compared to the parent TrGA PI.
  • the PI is calculated from the specific activities (activity/mg enzyme) of the WT and the variant enzymes. It is the quotient "Variant-specific activity/WT-specific activity.”
  • the PI of the specific activity for the wildtype TrGA was 1.0 and a variant with a PI > 1.0 had a specific activity that was greater than the parent TrGA.
  • the specific activity was the activity measured by the ethanol screening assay divided by the results obtained in the Caliper assay described above.
  • Table 4 provides the variants having a performance index of at least 1.0. These included the following sites: 10, 14, 15,23,59,60,61,65,67,68,72,73,97,98,99, 102, 110, 113, 133, 140, 144, 145, 147, 152, 153, 164, 182,204,205,214,216,219,228,229,230,231,236,239,241,242,263,264, 265, 268, 269, 276, 284, 291, 300, 301, 303, 311, 338, 342, 344, 346, 349, 359, 361, 364, 375, 379, 382, 390, 391, 393, 394, 410, 417, 418, 430, 431, 433, 442, 444, 448, and 451.
  • the sites showing the highest specific activity (having a performance index above 1.2), included: 61, 67, 72, 97, 102, 133, 145, 153, 205, 219, 228, 230, 231, 239, 263, 268, 291, 311, 342, 394, 430, 431 and 451.
  • Table 5 shows the variants that had a performance index of 1.0 or better as compared to the parent for both properties: specific activity and thermostability. These included the following sites: 10, 15, 59, 61, 68, 72, 73, 97, 99, 102, 133, 140, 153, 182, 204, 205, 214, 228, 229, 230, 231, 236, 241, 242, 264, 265, 268, 275, 284, 291, 300, 301, 303, 311, 338, 344, 346, 359, 361, 364, 375, 370, 382, 391, 393, 394, 410, 417, 430, 431, 433, 444, 448, and 451.
  • TrGA protein material used for all crystallization experiments was initially purified in one step by anion exchange chromatography as follows: concentrated culture supernatants of expressed TrGA, consisting of 180 mg/ml total protein, were prepared by diluting sample 1 : 10 in a 25 mM Tris-HCl, pH 8.0 buffer. A HIPREP 16/10 Q Sepharose FF column (GE Helthcare) was employed for the anion exchange purification. The HIPREP column was equilibrated with 4 column volumes (CV) starting buffer (25 mM Tris-HCl, pH 8.0) followed by application of 10 ml of the diluted protein sample.
  • CV column volumes
  • the TrGA sample was diluted after the last concentration step in distilled water until a conductivity of the protein sample was reached that corresponded to the conductivity of the starting buffer of the anion purification, i.e. 25 mM Tris-HCl, pH 8.0.
  • the MONOQ column was first equilibrated with 4 column volumes (CV) starting buffer, followed by application of the diluted protein sample to the column. Bound protein was eluted from the MONOQ column by two different gradients. In the first a 4 CV linear pH gradient was applied where the pH of the starting buffer was decreased from 8.0 to 6.0.
  • Protein crystallization The protein sample that was used to find the initial TrGA crystallization conditions was a sample of the TrGA material that was purified once by anion exchange purification and thereafter stored at -20°C. The TrGA protein sample was thawed and diluted with 50 mM sodium acetate buffer, pH 4.3, to approximately 12 mg/ml, prior to the initial crystallization experiments.
  • TrGA crystals were found to grow in solution consisting of 25% PEG 3350, 0.20M ammonium acetate, 0.1 OM Bis-Tris pH 5.5 (reservoir solution), using the vapor-diffusion method with hanging drops (McPherson 1982), at 20° C. Crystallization drops were prepared by mixing equal amounts of protein solution (12 mg/ml) and reservoir solution to a final volume of 10 ⁇ l.
  • the orthorhombic X-ray dataset was used to solve the TrGA structure by molecular replacement (MR) and the high resolution orthorhombic dataset was used for the final orthorhombic space group TrGA structure model.
  • the C centered monoclinic dataset was collected from a single frozen TrGA crystal at 10OK, equilibrated in a cryo-protective agent comprised of 25% PEG 3350, 15% Glycerol 50 mM CaCI 2 and 0.1 M Bis-Tris pH 5.5 as cryoprotectant, mounted in rayon-fiber loops, and plunge frozen in liquid nitrogen prior to transportation to the synchrotron.
  • the high-resolution orthorhombic (1.9 A) data set and the C centric monoclinic dataset (1.8 A) were both collected at a synchrotron source, beam line 91 1 :5 at MAX LAB in Lund, Sweden. Both datasets that were collected at a synchrotron source were processed with MOSFLM, and scaled with program SCALA included in the CCP4 program package (Collaborative Computational Project Number 4 1994). All subsequent data processing was performed using the CCP4 program package (Collaborative Computational Project Number 4 1994), unless otherwise stated. A set of 5% of the reflections from each data set was set aside and used for monitoring the R-free (Brunger, A (1992) Nature, 355: 472-475).
  • TrGA structure was initially solved by MR with the automatic replacement program MOLREP (Collaborative Computational Project Number 4 1994), included in the CCP4 program package, using the initial lo-resolution orthorhombic dataset, and using the coordinates of Aspergillus awamori GA (AaGA) variant Xl OO (pdb entry IGLM (Aleshin, et al (1994) J. MoI. Biol. 238:575-591 ) as search model.
  • the A. awamori GA search model was edited to remove all glycosylation moieties attached to the protein molecule as N- and O- glycosylations, and all solvent molecules before carrying out the MR experiments.
  • the initial TrGA structure model was refined with alternating cycles of model building using Coot (Emsley et al, (2004) Acta Crystallogr D Biol Crystallogr 60:2126-32), and maximum likelihood refinement using Refmac 5.0.
  • the resolution of the initial TrGA structure model was extended to the resolution of the high- resolution orthorhombic dataset (1.9A) by refining the initial TrGA structure model against the high- resolution dataset for 10 cycles of restrained refinement using the program Refmac 5.0.
  • Most water molecules in the structure models were located automatically by using the water picking protocols in the refinement programs, and then manually selected or discarded by inspection by eye. All structural comparisons were made with either Coot (Emsley et al. (2004) supra) or O (Jones et al. (1991) Acta
  • TrGA catalytic core segment followed the same ( ⁇ / ⁇ ) 6 - barrel topology described by Aleshin et al. (1992, supra) for the AaGA, consisting of a double barrel of alpha helices with the C-terminal of the outer helix leading into the N-terminus of an inner helix. It was possible to identify key differences in the electron density such as the disulfide bridge between residues 19 and 26 and ar insertion (residues 257-260) relative to AaGA. The segment comprising 80-100 also underwent extensive model rebuilding. One major glycosylation site was identified at Asn 171 , which had up to four glycoside moieties attached.
  • Example 9 Homology between TrGA and Aspergillus awamori GA [218]
  • the crystal structure of the TrGA identified in Example 8 was superposed on the previously identified crystal structure of the Aspergillus awamori GA (AaGA).
  • the AaGA crystal structure was obtained from the protein database (PDB) and the form of AaGA that was crystallized was the form containing only a catalytic domain.
  • the structure of the Trichoderma reesei glucoamylase with all three regions intact was determined to 1.8 Angstrom resolution herein (see Table 6 and Example 8).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP08742678A 2006-10-10 2008-04-08 Glucoamylase variants with altered properties Withdrawn EP2195423A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES12164788.7T ES2518916T3 (es) 2007-10-09 2008-04-08 Variantes de glucoamilasa con propiedades modificadas
EP12164776.2A EP2479264B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties
DK12164776.2T DK2479264T3 (da) 2007-10-09 2008-04-08 Glucoamylasevarianter med ændrede egenskaber
EP12164788.7A EP2479265B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties
PL12164788T PL2479265T3 (pl) 2007-10-09 2008-04-08 Odmiany glukoamylazy o zmienionych właściwościach
DK12164788.7T DK2479265T3 (da) 2006-10-10 2008-04-08 Glucoamylasevarianter med ændrede egenskaber
PL12164776T PL2479264T3 (pl) 2007-10-09 2008-04-08 Odmiany glukoamylazy o zmienionych właściwościach

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2007/021683 WO2008045489A2 (en) 2006-10-10 2007-10-09 Glucoamylase variants with altered properties
PCT/US2008/004574 WO2009048488A1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP12164788.7A Division EP2479265B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties
EP12164776.2A Division EP2479264B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties

Publications (1)

Publication Number Publication Date
EP2195423A1 true EP2195423A1 (en) 2010-06-16

Family

ID=39720559

Family Applications (6)

Application Number Title Priority Date Filing Date
EP12164776.2A Active EP2479264B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties
EP08742678A Withdrawn EP2195423A1 (en) 2006-10-10 2008-04-08 Glucoamylase variants with altered properties
EP12169318.8A Not-in-force EP2514818B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants
EP12164788.7A Active EP2479265B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties
EP12157549.2A Active EP2481796B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants
EP08742666A Withdrawn EP2195422A1 (en) 2007-10-09 2008-04-08 Glucoamylase variants

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12164776.2A Active EP2479264B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP12169318.8A Not-in-force EP2514818B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants
EP12164788.7A Active EP2479265B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants with altered properties
EP12157549.2A Active EP2481796B1 (en) 2007-10-09 2008-04-08 Glucoamylase variants
EP08742666A Withdrawn EP2195422A1 (en) 2007-10-09 2008-04-08 Glucoamylase variants

Country Status (9)

Country Link
EP (6) EP2479264B1 (da)
JP (2) JP5594898B2 (da)
CN (1) CN102776164B (da)
BR (1) BRPI0817853B1 (da)
CA (5) CA2702024C (da)
DK (3) DK2479264T3 (da)
ES (4) ES2516265T3 (da)
PL (4) PL2514818T3 (da)
WO (2) WO2009048488A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141779A1 (en) 2009-06-03 2010-12-09 Danisco Us Inc. Cellulase variants with improved expression, activity and/or stability, and use thereof
CN102712915B (zh) * 2009-08-19 2014-12-10 丹尼斯科美国公司 具有改良比活和/或热稳定性的葡糖淀粉酶的组合变体
PE20121504A1 (es) 2009-08-19 2012-11-05 Dupont Nutrition Biosci Aps Variantes de glucoamilasa
DK2599861T3 (da) 2009-11-20 2017-11-06 Danisco Us Inc Beta-glucosidasevarianter med forbedrede egenskaber
WO2011127802A1 (en) * 2010-04-14 2011-10-20 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2012019169A1 (en) 2010-08-06 2012-02-09 Danisco Us Inc. Production of isoprene under neutral ph conditions
EP2561083B1 (en) 2010-08-06 2017-01-11 Danisco US Inc. Use of Humicola grisea glucoamylase in an SSF process at neutral pH
MX2013010510A (es) 2011-03-17 2013-10-07 Danisco Inc Enzimas glocosil hidrolasa y usos de estas para la hidrolisis de biomasa.
JP2014512829A (ja) 2011-04-29 2014-05-29 ダニスコ・ユーエス・インク デンプンを液化及び糖化して高密度グルコースシロップを調製するための単一ｐＨプロセス
WO2013022799A1 (en) 2011-08-05 2013-02-14 Danisco Us Inc. PRODUCTION OF ISOPRENOIDS UNDER NEUTRAL pH CONDITIONS
US9540669B2 (en) * 2012-08-14 2017-01-10 Danisco Us Inc. Trichoderma reesei glucoamylase variants resistant to oxidation-related activity loss and the use thereof
MX2015002099A (es) 2012-08-22 2015-05-11 Dupont Nutrition Biosci Aps Variantes que tienen actividad glucoamilasa.
CN102994476B (zh) * 2012-11-27 2014-03-12 山东蔚蓝生物科技有限公司 一种糖化酶
CN104870641A (zh) 2012-12-12 2015-08-26 丹尼斯科美国公司 纤维二糖水解酶的变体
CN104870642A (zh) 2012-12-12 2015-08-26 丹尼斯科美国公司 纤维二糖水解酶的变体
US20160272959A1 (en) 2012-12-12 2016-09-22 Danisco Us Inc. Variants of cellobiohydrolases
EP2931887A1 (en) 2012-12-12 2015-10-21 Danisco US Inc. Variants of cellobiohydrolases
WO2014093281A1 (en) 2012-12-12 2014-06-19 Danisco Us Inc. Variants of cellobiohydrolases
WO2014135647A1 (en) * 2013-03-07 2014-09-12 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
JP2016533741A (ja) 2013-07-29 2016-11-04 ダニスコ・ユーエス・インク 酵素の変異体
ES2749211T3 (es) 2013-12-04 2020-03-19 Danisco Us Inc Variantes de glucoamilasa
EP3712240B1 (en) 2014-02-07 2023-09-27 Novozymes A/S Compositions for producing glucose syrups
MX2017007102A (es) 2014-12-01 2017-08-24 Novozymes As Produccion mejorada de jarabes de glucosa.
CN113403357A (zh) 2014-12-19 2021-09-17 丹尼斯科美国公司 葡糖淀粉酶共混物
WO2018106656A1 (en) 2016-12-06 2018-06-14 Danisco Us Inc Truncated lpmo enzymes and use thereof
CZ308536B6 (cs) * 2017-10-10 2020-11-11 Fyzikální ústav AV ČR, v.v.i. Luminofory na bázi Eu2+ a Eu2+/Ce3+ dopovaných granátů
WO2021007379A1 (en) 2019-07-09 2021-01-14 Dupont Nutrition Biosciences Aps Fat coated particulate enzyme compositions
WO2021046073A1 (en) 2019-09-05 2021-03-11 Dupont Nutrition Biosciences Aps Feed composition
KR20240060703A (ko) 2021-09-27 2024-05-08 인터내셔널 엔＆에이치 덴마크 에이피에스 사료 첨가제 조성물 및 이의 사용 방법
WO2023225510A1 (en) 2022-05-17 2023-11-23 Dupont Nutrition Biosciences Aps Feed additive comprising enzyme combinations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5534046A (en) 1978-09-01 1980-03-10 Cpc International Inc Novel glucoamyrase having excellent heat resistance and production
GB2089836B (en) 1980-12-16 1984-06-20 Suntory Ltd Process for producing alcohol by fermentation without cooking
US4794175A (en) 1983-12-20 1988-12-27 Cetus Corporation Glucoamylase CDNA
US4618579A (en) 1984-09-28 1986-10-21 Genencor, Inc. Raw starch saccharification
JPH0630586B2 (ja) 1984-12-15 1994-04-27 サントリー株式会社 グルコアミラ−ゼ遺伝子
ATE117020T1 (de) 1985-08-29 1995-01-15 Genencor Int Expression von heterologen polypeptiden in filamentösen pilzen, verfahren zu deren herstellung und vektoren zu deren herstellung.
US5024941A (en) 1985-12-18 1991-06-18 Biotechnica International, Inc. Expression and secretion vector for yeast containing a glucoamylase signal sequence
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988009795A1 (en) 1987-06-06 1988-12-15 Biotechnica International, Inc. Yeast expression vector
US6803499B1 (en) 1989-08-09 2004-10-12 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US6777589B1 (en) 1990-01-22 2004-08-17 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5290474A (en) 1990-10-05 1994-03-01 Genencor International, Inc. Detergent composition for treating cotton-containing fabrics containing a surfactant and a cellulase composition containing endolucanase III from trichoderma ssp
US5246853A (en) 1990-10-05 1993-09-21 Genencor International, Inc. Method for treating cotton-containing fabric with a cellulase composition containing endoglucanase components and which composition is free of exo-cellobiohydrolase I
EP1416045A1 (en) 1990-10-05 2004-05-06 Genencor International, Inc. Composition containing a fungal cellulase for the treatment of cotton-containing fabrics
US5475101A (en) 1990-10-05 1995-12-12 Genencor International, Inc. DNA sequence encoding endoglucanase III cellulase
JPH06503960A (ja) 1990-12-10 1994-05-12 ジェネンコア　インターナショナル　インコーポレーテッド ＴＲＩＣＨＯＤＥＲＭＡ　ＲＥＥＳＥＩのβ−グルコシダーゼ遺伝子のクローニングおよび増幅によるセルロースの改良糖化
US5861271A (en) 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
CN1151762A (zh) 1994-06-30 1997-06-11 诺沃诺尔迪斯克生物技术有限公司 非毒性、非产毒性、非致病性镰孢属表达系统及所用启动子和终止子
US5744716A (en) 1995-06-08 1998-04-28 Scp Global Technologies, A Division Of Preco, Inc. Fluid displacement level, density and concentration measurement system
US6255084B1 (en) 1997-11-26 2001-07-03 Novozymes A/S Thermostable glucoamylase
DK1032654T3 (da) * 1997-11-26 2009-05-11 Novozymes As Thermostabil glucoamylase
EP1097196B2 (en) * 1998-07-15 2011-04-20 Novozymes A/S Glucoamylase variants
US6268328B1 (en) 1998-12-18 2001-07-31 Genencor International, Inc. Variant EGIII-like cellulase compositions
US6254914B1 (en) 1999-07-02 2001-07-03 The Board Of Trustees Of The University Of Illinois Process for recovery of corn coarse fiber (pericarp)
JP2003504046A (ja) * 1999-07-09 2003-02-04 ノボザイムス アクティーゼルスカブ グルコアミラーゼ変異体
AU2001279254A1 (en) 2000-08-11 2002-02-25 Genencor International, Inc. Bacillus transformation, transformants and mutant libraries
US6582914B1 (en) 2000-10-26 2003-06-24 Genencor International, Inc. Method for generating a library of oligonucleotides comprising a controlled distribution of mutations
US6309872B1 (en) * 2000-11-01 2001-10-30 Novozymes Biotech, Inc Polypeptides having glucoamylase activity and nucleic acids encoding same
US7371546B2 (en) * 2001-10-01 2008-05-13 Novozymes A/S Glucoamylase variants
GB0129864D0 (en) 2001-12-13 2002-02-06 Danisco Animal feed
EP2166091A3 (en) 2003-03-10 2015-06-10 Novozymes A/S Alcohol product processes
EP1603406B1 (en) 2003-03-10 2012-10-24 POET Research, Inc. Method for producing ethanol using raw starch
EP1862540B1 (en) 2003-05-29 2011-09-14 Genencor International, Inc. Novel trichoderma genes
US6899910B2 (en) 2003-06-12 2005-05-31 The United States Of America As Represented By The Secretary Of Agriculture Processes for recovery of corn germ and optionally corn coarse fiber (pericarp)
NZ526666A (en) 2003-07-14 2004-11-26 Propeller Jet Ltd Impeller drive for a jet propulsion unit
AU2004293789B2 (en) 2003-11-21 2009-07-23 Genencor International, Inc. Expression of granular starch hydrolyzing enzymes in trichoderma and process for producing glucose from granular starch substrates
US9236043B2 (en) 2004-04-02 2016-01-12 Knfb Reader, Llc Document mode processing for portable reading machine enabling document navigation
US7413887B2 (en) 2004-05-27 2008-08-19 Genecor International, Inc. Trichoderma reesei glucoamylase and homologs thereof
AU2004320371B2 (en) 2004-05-27 2011-09-22 Genencor International, Inc. Heterologous expression of an aspergillus kawachi acid-stable alpha amylase and applications in granular starch hydrolysis
GB0423139D0 (en) 2004-10-18 2004-11-17 Danisco Enzymes
WO2006060062A2 (en) * 2004-11-30 2006-06-08 Genencor International, Inc. Trichoderma reesei glucoamylase and homologs thereof
US20080280328A1 (en) * 2005-11-18 2008-11-13 Novozymes A/S Glucoamylase Variants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009048488A1 *

Also Published As

Publication number Publication date
CA2948231C (en) 2020-12-29
JP2011500020A (ja) 2011-01-06
BRPI0817853B1 (pt) 2022-05-10
CN102776164B (zh) 2014-03-12
DK2481796T3 (da) 2014-08-04
ES2518916T3 (es) 2014-11-05
WO2009048488A1 (en) 2009-04-16
EP2195422A1 (en) 2010-06-16
CA3069361A1 (en) 2009-04-16
ES2502743T3 (es) 2014-10-06
EP2481796B1 (en) 2014-06-11
DK2514818T3 (da) 2014-08-04
WO2009048487A1 (en) 2009-04-16
PL2479264T3 (pl) 2014-11-28
CA2702019A1 (en) 2009-04-16
PL2479265T3 (pl) 2014-11-28
CA3069377A1 (en) 2009-04-16
ES2504983T3 (es) 2014-10-09
EP2514818B1 (en) 2014-06-18
PL2514818T3 (pl) 2014-11-28
EP2479264B1 (en) 2014-06-18
JP2011500019A (ja) 2011-01-06
JP5463292B2 (ja) 2014-04-09
PL2481796T3 (pl) 2014-11-28
EP2514818A2 (en) 2012-10-24
CA3069361C (en) 2023-11-28
EP2479265B1 (en) 2014-06-11
DK2479264T3 (da) 2014-08-04
CA3069377C (en) 2022-11-08
CA2702019C (en) 2017-01-03
JP5594898B2 (ja) 2014-09-24
CA2948231A1 (en) 2009-04-16
CA2702024C (en) 2020-04-28
EP2479264A1 (en) 2012-07-25
EP2514818A3 (en) 2013-04-24
ES2516265T3 (es) 2014-10-30
EP2481796A1 (en) 2012-08-01
CN102776164A (zh) 2012-11-14
CA2702024A1 (en) 2009-04-16
EP2479265A1 (en) 2012-07-25
BRPI0817853A2 (pt) 2014-10-14

Similar Documents

Publication Publication Date Title
US11130946B2 (en) Glucoamylase variants with altered properties
EP2479264B1 (en) Glucoamylase variants with altered properties
US8592194B2 (en) Glucoamylase variants with altered properties
US9290753B2 (en) Glucoamylase variants with altered properties
US20120164695A1 (en) Combinatorial variants of glucoamylase with improved specific activity and/or thermostability

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20101025

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120504